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Epithelial Ovarian Cancer (EOC) is the fifth leading cause of cancer death in women 
worldwide. Its high mortality rate is mainly due to late diagnosis, when tumors are spread 
out into the abdominal cavity. The standard care for patients combines radical surgery with 
platinum-taxol chemotherapy. Despite a good initial response, development of a platinum 
resistant disease is a frequent event in advanced EOC patients and predicts poor 
prognosis. Thus, improving response to platinum represent an unmet goal in EOC 
treatment. We have recently contributed to this issue reporting the molecular and 
biological characterization of three out of the seven new isogenic models of platinum 
resistant (PT-res) EOC cell lines we have generated in the lab: MDAH-2774, TOV-112D 
and OVSAHO. Our characterization pointed out a higher ability of the three isogenic PT-
res cells to resolve PT-induced DNA damage, compared to parental cells, suggesting that 
drug uptake, detoxification and excretion, along with the DNA repair pathway, play a 
central role in the instauration of a resistant phenotype. Moreover, all PT-res cells 
displayed an evident change in their morphology, accompanied by higher ability to grow 
on mesothelium. This included a reorganization of cytoskeleton, cell-cell junctions and 
adhesion abilities. We went deeper in the biological and molecular characterization of 
MDAH-2774 PT-res cells reporting the appearance of a novel mutation (S185G), that 
accompanied the already present R273H, in TP53 gene. This additional mutation, likely 
induced by platinum, was associated with higher p53 phosphorylation on Ser37 that might 
confer increased activity to an already mutated TP53. Its expression had functional 
consequences, since it significantly increased PT-resistance in SKOV3 (p53NULL) cells and 
was associated with the higher PT-resistant phenotype in MDAH cells. Mechanistically, our 
results suggest that the more active p53S185G/R273H protein, in MDAH cells, was at least 
partially responsible for an altered progression through the M phase of the cell cycle, that 
eventually results in deregulated mitosis with the appearance of a subpopulation of 
enlarged multinucleated cells (MNGCs). Indeed, TP53MUT specifically regulates the 
transcription of mitotic-regulator genes, supporting the possibility that it confers a surviving 
advantage to aberrant mitotic cells. Future studies are necessary to properly clarify the 
molecular mechanisms underlying the formation of MNGCs and how p53S185G/R273H 







1.1 Epithelial Ovarian Cancer (EOC) 
Ovarian cancer is the fifth leading cause of cancer death in women and the most lethal 
gynecologic malignancy. This is mostly due to late diagnosis, when tumors are spread out 
into the abdominal cavity, and to the occurrence of chemoresistance (Jayson et al., 2014). 
Histologically ovarian cancer is roughly composed of epithelial, germ cell and stromal 
tumors, with epithelial ovarian cancer (EOC) being the most common and the most deadly, 
with five-year survival rates below 40%.  
Several distinctive morphology and molecular features can be used to classify epithelial 
ovarian carcinomas into different types. The serous type is the most common, and can 
include high grade and low grade tumors. The other main types 
include mucinous, endometrioid, and clear cell. Type I tumors tend to grow slowly and 
cause fewer symptoms. These tumors usually do not respond well to chemotherapy. Low 
grade serous carcinoma, clear cell, mucinous and endometrioid carcinoma are examples 
of type I tumors. They are frequently mutated in genes like KRAS, BRAF, PTEN and -
catenin. Type II tumors grow fast and tend to spread sooner. These tumors tend to 
respond better to chemotherapy. High grade serous carcinoma is an example of a type II 
tumor. They are characterized by a high genomic instability and mutations in TP53 gene. 
Moreover homologous recombination repair pathways are altered in roughly 50% of high 
grade serous ovarian cancers in fact, hereditary tumors associated with BRCA1 and 
BRCA2 mutations belong to Type II (Jayson et al., 2014; Kurman and Shih, 2010).  
The International Federation of Gynecology and Obstetrics (FIGO) proposes a four-steps 
staging for EOC: Stage I) The cancer is only in the ovary or fallopian tubes; Stage II) The 
cancer is in one or both ovaries or fallopian tubes and has spread to other organs (such as 
the uterus, bladder, the sigmoid colon, or the rectum) within the pelvis or there is primary 
peritoneal cancer; Stage III) Tumor involves one or both ovaries or fallopian tubes, or 
primary peritoneal cancer, with cytologically or histologically confirmed spread to the 
peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes and 
Stage IV) Distant metastasis excluding peritoneal metastases (Prat, 2015).  
Standard care for patients combines radical surgery with platinum-based chemotherapy. 
The standard first-line treatment combines two different types of drugs, a platinum 
compound (usually cisplatin or carboplatin) and a taxane (usually paclitaxel or docetaxel). 
Paclitaxel is an antitumoral drug that enhances the polymerization of tubulin to stable 
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microtubules and also interacts directly with microtubules, stabilizing them against 
depolymerization. The fact that the drug has a specific binding site on the microtubule 
polymer makes it unique among chemotherapeutic agents (Horwitz, 1994). The 
chemotherapeutic mechanism of platinum compounds is typical of DNA-binding alkylating 
agents. Platinum compounds exert their anti-tumor activity through the formation of 
intrastrand and interstrand cross-links, interfering with DNA repair mechanisms, causing 
single-strand and double-strand breaks (DNA damage), and subsequently inducing cell 
cycle arrest in S and G2 phases, if the damage is limited, or inducing apoptosis in cancer 
cells, when the DNA damage is extended (Cook and Brenton, 2011). Although this 
treatment regime is effective as the first-line treatment, recurrence occurs in up to 75% of 
ovarian cancer patients. Patients with recurrent ovarian cancer ultimately develop 
resistance to chemotherapy that led to the progression of the disease (Jayson et al., 
2014). 
 
1.2 Drug resistance in EOC 
1.2.1 Clinical resistance 
Improving response to platinum represents an unmet goal in EOC treatment, since 
platinum resistance is the main contributing factor in cancer-associated mortality. Time to 
relapse after first-line platinum-based therapy affects the subsequent treatment options 
(Figure 1). Platinum-refractory patients, who have progressive disease during initial 
treatment, represent about 14% of cases and have an intrinsic drug resistance. Despite of 
good initial response, the majority of patients relapse and are classified according to 
likelihood of response to secondary platinum treatment. Those who have a platinum free 
interval (PFI) within 6 months of ending first treatment are classified as platinum resistant. 
Patients who relapse more than 12 months later are termed platinum sensitive. Patients 
who relapse between 6 and 12 months are classified as partially sensitive (Cooke and 





   
Figure 1. Likelihood of patients response to secondary platinum treatment. Patients are classified as 
refractory, platinum resistant, platinum sensitive and partially sensitive according to time to relapse after 
initial platinum treatment (from Cooke and Brenton, 2011).  
 
EOC is described as having an extensive intra-tumoral heterogeneity with multiple, 
genetically distinct clones forming the entire tumor bulk. Intrinsic platinum-resistant cancer 
cells exist in ovarian tumors before treatment and are selected once treatment has killed 
their platinum-sensitive counterparts (Figure 2). This results in repopulation of the tumor, 
and a low probability that it will respond to further treatments with platinum-based drugs 
(Holmes, 2015; Cooke and Brenton, 2011). In the absence of any pre-existing resistant 
cells within the cancer mass, relapse in patients with platinum-sensitive EOC is caused by 
regeneration of tumor bulk by residual platinum-sensitive cells. Cell divisions during the 
regrowth can lead to the occurrence of resistance mutations. Whether further relapses are 
sensitive or not to platinum, therefore, reflects the stochastic nature of mutation (Cooke 
and Brenton, 2011). The process that lead to refractory disease might be basically 
different from those that lead to initially sensitive EOC. 
 
1.2.2 Molecular mechanisms of platinum resistance 
The platinum-resistant cells use a complex repertoire of mechanisms to mitigate the 
effects of platinum therapy, including DNA damaging repair, decreased drug uptake, 
increased platinum removal, sequestration of the metal into lysosomes and occurrence of 





Figure 2. Platinum resistance development in EOC. As indicated, platinum-resistant cells (green) are 
present in the tumor before treatment and they are selected once the chemotherapy has killed their platinum-





Figure 3. Major mechanisms of primary and acquired resistance in EOC. Resistant cells develop 
resistance mechanisms, including DNA damaging repair, decreased drug uptake, increased platinum 
removal, sequestration of the metal into lysosomes and occurrence of resistance mutations (from Freimund 
et al., 2018).  
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The therapeutic activity of platinum compounds is mediated by an active species, formed 
by aqueous hydrolysis as the drug enters the cell. This active species interacts with DNA, 
RNA and protein, but the cytotoxic effect seems to be primarily mediated via the formation 
of DNA interstrand and intrastrand crosslinks (Argawal and Kaye, 2003). Two categories of 
resistance to platinum have been identified: those that limit platinum-DNA adduct 
formation and those that prevent cell death after the formation of platinum-DNA adduct 
(Freimund et al., 2018).  
 
1.2.2.1 Deregulation of cisplatin transporters 
One of the most prominent characteristics of cellular resistance to cisplatin is the reduced 
accumulation of the compound into the cell. As a consequence of reduced uptake or 
retention, the formation of platinum-DNA adducts is decreased. Several transporters, 
which are expressed on the cell membranes, have been associated with cisplatin transport 
across the plasma membrane and with resistance: the copper transporter 1 (Ctr1), the 
copper transporter 2 (Ctr2), the P-type copper-transporting ATPases ATP7A and ATP7B, 
and the ATP-binding cassette transporter known for years as P-glycoprotein or MDR1 
(Ciarimboli, 2014). The two copper transporters, ATP7A and ATP7B, are expressed at 
higher levels in platinum-resistant cell lines and have been functionally implicated in 
resistance to several platinum agents, including cisplatin (Samimi et al., 2004; Katano et 
al., 2004; Katano et al., 2003). ATP7A and ATP7B are members of the P-type ATPase 
family of transporters. Their primary function is to transport copper into the lumen of 
the trans-Golgi network (TGN) for the biosynthesis of copper-dependent enzymes and to 
facilitate export of excess copper from the cell by sequestering copper into exocytic 
vesicles. Cu-ATPases bind copper at their large NH2-terminal domain and then transfer 
copper across the membrane using the energy of ATP hydrolysis. Therefore, the major 
mechanism through which overexpression of ATP7B increases resistance to cisplatin 
seems to involve blockade of drug access to the nucleus. This may be due either to 
ATP7B pumping cisplatin into the lumen of the TGN and, similarly to copper exposure, 
cisplatin also alters the subcellular localization of ATP7B, resulting in its translocation from 
the Golgi apparatus to peripheral vesicles, presumably lysosomes (Zhitomirsky et Assaraf, 
2016). Studies have demonstrated that small interfering RNA silencing of ATP7B 
increases DNA adduct formation in platinum-resistant EOC lines, and when used with 
cisplatin in vivo, a decrease in tumor growth was observed, highlighting a potential method 
to circumvent platinum resistance (Mangala et al., 2009).  
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The copper transporter Ctr1 is a major determinant of cisplatin uptake and sensitivity, 
which could be modulated by copper levels. It has been observed that in different cisplatin-
resistant cell lines and ovarian cancer cell lines derived from patients, where the platinum-
based chemotherapy failed, the resistance against cisplatin is associated with reduced 
expression of the Ctr1 (Liang et al., 2012). Other lines of evidence of the importance of 
Ctr1 expression for efficacy of treatment with platinating agents derive from the study of 
the Ctr1-mRNA expression in 40 women with ovarian carcinoma: high Ctr1 expression 
was significantly associated with sensitivity to platinum-based chemotherapy and 
progression-free survival. Conversely, low Ctr1 expression was significantly associated 
with resistance to platinum-based chemotherapy and the shortest survival (Lee et al., 
2011). Copper transporter 2 (Ctr2) is in the same family as Ctr1, and primarily localized in 
intracellular vesicles, in particular in lysosomes and late endosomes as well as on the 
plasma membrane of several tumor cell lines (Huang et al., 2014; van den Berghe et al., 
2007). Based on its structural similarity to the plasma membrane Ctr1, it has been 
postulated that Ctr2 may mediate copper and cisplatin efflux from lysosomes and late 
endosomes into the cytoplasm (Huang et al., 2014). Thus, it seemed reasonable that Ctr2 
overexpression would increase cell sensitivity to cisplatin, due to increased release of 
cisplatin from lysosomes. Accordingly, one would suggest that reduced expression of Ctr2 
could render cells resistant to cisplatin due to reduced drug efflux from the lysosomes into 
the cytoplasm. Surprisingly, an analysis of Ctr2 expression levels and cisplatin cytotoxicity 
in six ovarian carcinoma cell lines identified a direct correlation between Crt2 expression 
levels and cisplatin resistance (Blair et al., 2009). A possible explanation for this Ctr2-
mediated cisplatin resistance is based on its ability to mediate cisplatin endocytosis 
(Zhitomirsky et Assaraf, 2016). 
ABC transporters catalyze the ATP-dependent transport of various anticancer drugs out of 
tumor cells (van Veen and Konings, 1998; Borst and Elferink, 2002). Overexpression of 
ABC drug transporters is related to gene amplification, transcriptional and epigenetic 
changes (Choi and Yu, 2014) and has been shown to be responsible for the major portion 
of multidrug resistance (Choi, 2005). The most widely studied ABC transporter is the P-
glycoprotein or human MDR1. It has been proposed to act as ‘hydrophobic vacuum 
cleaner’ because of its ability to remove both lipids and drugs as they intercalate and 
diffuse through the cell membrane. The protein sequences of lipid and drug ABC 
transporters are similar and probably reflect a common transport mechanism. Human 
MDR3, for example, is a well-characterized phosphatidyl-choline flippase and has 73% 
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protein sequence identity to human MDR1. In fact, human MDR1 is itself a lipid flippase 
transporting short chain phospholipids (Chang, 2003; Choi and Yu, 2014). In addition to 
facilitate drug export from the cell, other mechanisms of ABC transporters-mediated drug 
resistance have been reported; these include active lysosomal drug sequestration 
mediated by these transporters (Figure 4) (Zhitomirsky and Assaraf, 2016). Therefore, to 
improve therapeutic response of patients, should be used anticancer agents which do not 
interact with any of this kind of transporters (despite an extremely wide recognition 
pattern). Thus, MDR modifying agents which inhibit the function of the MDR proteins, 
either competitively or non-competitively, are good candidates for such a pharmacological 




Figure 4. MDR transporters mediate platinum resistance. Transporters from the ABC superfamily localize 
on the plasma membrane, and facilitate drug efflux from the cell. In addition, some ABC transporters were 
found to localize on lysosomes and mediate active transport of drugs into the lysosome, facilitating 
lysosomal drug sequestration (from Zhitomirsky and Assaraf, 2016). 
 
1.2.2.2 Detoxification of cisplatin 
There is also an extensive body of evidence implicating the enzyme that catalyzes GSH 
synthesis (γ-glutamylcysteine synthetase), or the enzyme that mediates the conjugation 
between cisplatin and GSH (glutathione S-transferase, GST) in platinum resistance 
through their role in the conversion of cisplatin to inactivated conjugates and detoxification 
of cisplatin, respectively. GSTs make the compound more anionic and more readily 
exported from cells by the ATP-dependent glutathione S-conjugate export (GS-X) pumps 
(MRP1 or MRP2). Increased levels of other low-molecular-weight thiol-containing proteins 
that are involved in heavy-metal binding and detoxification, the metallothioneins, have also 
been shown to lead to resistance to cisplatin (Kelland, 2007). 
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1.2.2.3 Proficient DNA repair 
After platinum-DNA adducts have been formed, cellular survival can occur either by DNA 
repair or removal of these adducts, or by tolerance mechanisms. Platinum compounds 
bind to DNA and create intra-strand/ inter-strand DNA cross-links that induce a DNA 
damage response (Figure 5). Repair of DNA lesions occurs through different DNA repair 
pathways, including nucleotide excision repair (NER), mismatch repair (MMR), and 




Figure 5. Tumor resistance to platinum drugs mediated after DNA binding. The main removal pathway 
for DNA adducts is the nucleotide-excision repair (NER); increased NER, especially through increased 
activity of the endonuclease protein ERCC1 (excision repair cross-complementing-1) can occur in tumors, 
and can lead to platinum drug resistance (as adducts are removed before apoptotic signaling pathways are 
triggered). In addition, resistance can occur through increased tolerance to platinum-DNA adducts - even 
though the DNA adducts are formed - either through loss of DNA mismatch repair, bypassing of adducts by 
polymerase β and η, or through downregulation of apoptotic pathways (from Kelland, 2007). 
 
NER is the major pathway known to remove cisplatin lesions from DNA (Kelland, 2007). 
Increased NER in cisplatin-resistant ovarian cancer cells was associated with increased 
expression of ERCC1 (excision repair cross-complementing-1) and XPF (xeroderma 
pigmentosum (XP), complementation group F) (Kelland, 2007). ERCC1 forms a 
heterodimer with XPF and acts to make a 5´ incision into the DNA strand, relative to the 
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site of platinated DNA. Increased tolerance to platinum-induced DNA damage can also 
occur through loss of function of the MMR pathway. Loss of this repair pathway leads to 
low-level resistance to cisplatin and carboplatin (Fink et al., 1996). During MMR, cisplatin-
induced DNA adducts are recognized by the MMR proteins MSH2, MSH3 and MSH6. It is 
postulated that cells then undergo several unsuccessful repair cycles, finally triggering an 
apoptotic response; loss of MMR with respect to cisplatin-DNA adducts therefore results in 
reduced apoptosis and, consequently, drug resistance (Kelland, 2007). The clinical 
relevance of the loss of MMR to platinum-drug-containing chemotherapy resistance, for 
example, in patients with ovarian cancer, is under active study; some data indicate a 
possible role in acquired drug resistance, whereas other data show no correlation with 
intrinsic resistance (Gifford et al., 2004; Kelland, 2007).  
HR is another major DNA repair pathway that plays an important role in repairing the DNA 
lesions induced by platinum-based agents. After NER-mediated identification and 
resolution of a DNA lesion, the process of HR “fills in” the resulting DNA gaps. HR-
dependent interstrand-crosslinking repair occurs during late S or G2 phase. It is well-
documented that critical components of the HR mechanism which mediate the repair of 
double-strand breaks (DSBs) are BRCA1 and BRCA2 (Couch et al., 2014). Although 
BRCA1 and BRCA2 have many pivotal roles in DNA repair, one of the most crucial roles 
seems to be direct binding of BRCA2 to the RAD51 protein to form a complex on the DNA. 
This complex leads to the recruitment of proteins, including MAPK, ATR, and p53, to the 
DNA lesions that initiates the HR repair process. HR repair of DNA lesions requires a 
second, homologous DNA that can act as a template for the repair reaction (Johnson and 
Jasin, 2001; Sung and Klein, 2006). Information from the homologous sequence is copied 
into the damaged site, allowing for the precise restoration of the original DNA sequence. 
EOC patients with germline mutations in BRCA1 and/or BRCA2 exhibit impaired ability to 
repair DNA lesions via HR. This event could potentially explain the increased sensitivity 
that these tumors have to platinum-based drugs (Cass et al., 2003).  
NHEJ is also involved in the repair of interstrand-crosslinking DNA lesions, but in contrast 
to HR, which repairs DSBs maintaining the genetic information contained in the 
homologous DNA strand, NHEJ often introduces errors while repairing the DNA lesion. 
First, the end-binding KU70/80 heterodimer complex binds to the DNA ends and activates 
DNA-dependent protein kinase catalytic subunits (DNA-PKs). Then the DNA lesion is 
removed, and finally, a DNA ligase IV-XRCC4 rejoins the two DNA ends. In contrast to 
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HR, NHEJ can generate translocations and/or deletions and is generally considered to be 
error-prone (Deans and West, 2011; Peng and Lin, 2011).  
Finally, tolerance might occur to platinum, and other cancer drugs, through decreased 
expression or loss of apoptotic signaling pathways (either the mitochondrial or death-
receptor pathways) as mediated through various proteins such as p53, anti-apoptotic and 
pro-apoptotic members of the BCL2 family, and JNK. 
 
1.3 The most frequent modulated genes in EOC 
To understand clonal origin and mutational adaptations associated with recurrent disease, 
whole-genome sequencing of tumors has been done by several groups (Cancer Genome 
Atlas Research Network, 2011; Castellarin et al., 2013; Patch et al., 2015). They reported 
that ubiquitous TP53 mutations were prevalent, extensive copy number changes, like 
CCNE1, inactivation of tumor suppressors RB1, NF1, RAD51B and PTEN genes and  
functional inactivation of homologous recombination repair genes. They observed multiple 
independent reversions of germline BRCA1 or BRCA2 mutations, loss of BRCA1 promoter 
methylation and recurrent promoter fusion associated with overexpression of the drug 
efflux pump MDR1 (Patch et al., 2015).  
 
1.3.1 CCNE1 amplification 
Cyclin E, a regulatory subunit for CDK2 that plays a key role in centrosome duplication, 
frequently is overexpressed in human cancers. Cyclin E1 overexpression 
and CCNE1 copy-number gain occurred in 23.3% and 14.8% of ovarian clear cell 
carcinomas, respectively, but they were not detected in any of the other endometriosis-
related tumors. The amplification and subsequent overexpression of CCNE1 have been 
reported as one of the major molecular mechanisms that promote the progression of 
ovarian high-grade serous carcinoma, the most common and aggressive type of ovarian 
cancer. Cyclin E1 has been established as a critical factor in the regulation of cell cycle 
progression, and overexpression of cyclin E1 has been reported to result in genomic 
instability. Cyclin E1 can inappropriately initiate DNA replication and centrosome 
duplication, which leads to chromosomal instability, aneuploidy, and eventually 
tumorigenesis (Kuhn et al., 2016; Kawamura et al., 2004). Further studies are required to 
determine whether cyclin E1 also contributes to the maintenance of telomeres in ovarian 
clear cell carcinomas and to determine the mechanisms involved. These results suggest 
the importance of CCNE1 in the progression of ovarian clear cell carcinoma and support 
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cyclin E1 as a possible therapeutic target in ovarian clear cell carcinoma; indeed, the 
presence of partially functional DNA repair pathway gives CCNE1-amplified cancers an 
advantage in surviving both platinum-based therapy and poly-ADP-ribose polymerase 
(PARP) inhibitor treatments (Kanska et al., 2016). 
 
1.3.2 BRCA1 / BRCA2 
BRCA1 and BRCA2 are genes mapping on two different chromosomes (17q21 and 
13q12.3, respectively). These genes are considered tumor suppressor genes, since they 
are deputed to the maintenance of genomic stability and hence to the control of cell growth 
(Yoshida and Miki, 2004). Germline BRCA1/2 mutations confer an increased risk of breast 
and High Grade Serous EOC (HGSOC), and, to a lesser extent, of other type of cancers 
(Madariaga et al., 2019). Approximately 15–20% of HGSOCs may be inherited with germ 
line mutations of BRCA1 and BRCA2 genes; however, the majority of HGSOC are 
sporadic, and a proportion of these present alterations in BRCA function through somatic 
mutations in BRCA1/2 genes or as a result of methylation (The Cancer Genome Atlas 
Research Network, 2011).  
Retrospective studies suggest that heterozygosity for a BRCA hereditary pathogenic 
variant (“BRCAness concept) in EOC patients is associated with a significantly more 
favorable prognosis and is predictive of sensitivity to combination therapies containing 
platinum derivates. BRCA1/2 gene mutations are a biomarker of sensitivity to treatment 
with PARP inhibitors in patients with advanced ovarian cancer. PARPs compose a family 
of more than 18 enzymes that play fundamental roles in DNA replication, DNA 
transcription and DNA damage repair. Many of these enzymes play a catalytic role in 
repairing damaged DNA. PARP-1, the most studied member of the PARP family, is an 
important factor for repairing single-strand breaks. Activation of PARP leads to increased 
activities of the BER and NER pathways in cells with a fully functional DDR/DNA repair 
capacity, but not in cells in which PARP is inhibited. PARP binds to SSBs through its N-
terminal zinc finger motifs, which activate its C-terminal domain to hydrolyze NAD+ (Figure 
6). This event produces long chains of ADP-ribose units (PARylation) and recruits factors 
of the BER complex (Krishnakumar and Kraus, 2010; Rouleau et al., 2010). The 
therapeutic effect of PARP inhibitors is due to “synthetic lethality”, which occurs in cells 
with non-functional double-strand DNA repair mechanism (homologous recombination, 
HR), like BRCA mutated cells. Once PARP-1 gene is deleted, it has been shown that 
SSBs collapse at the points of replication forks and result in DSBs. DSBs trigger HR repair 
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pathways to restore the DNA sequences that were disrupted. Farmer et al. showed that 
when BRCA1 or BRCA2 are defective, cells become sensitized to PARP inhibition, and 
this event results in chromosomal instability, cell cycle arrest, and apoptosis (Farmer et al., 




Figure 6. The therapeutic effect of PARP inhibitors is due to “synthetic lethality” in a “BRCAness” 
background. BRCA1 or BRCA2 mutation, resulting in a lack of homologous recombination, sensitizes cells 
to inhibition of PARP activity, which in turn leads to chromosomal instability, cell-cycle arrest, and 
subsequent apoptosis (from Sonnenblick et al., 2015). 
 
PARP inhibitors (e.g. Olaparib, Niraparib, Rucaparib) perform their anticancer effects only 
via their catalytic inhibition of PARPs in a landscape of BRCA deficiency and are used as 
maintenance therapy in patients with relapsed HGSOCs (Basourakos et al., 2017). BRCA 
testing is a prerequisite to agree upon PARP inhibitor therapy. 
 
1.3.3 TP53 
TP53 gene is the most frequently mutated tumor suppressor gene in human malignancy. 
Beyond the indisputable importance of p53 as a tumor suppressor, a wide number of new 
roles have recently been reported. It is known that p53 is a transcription factor and 
regulates the expression of a myriad of different target genes that then mediate the p53 
response. p53 binds specifically to DNA and regulates genes involved in cell cycle arrest, 
DNA repair, senescence, apoptosis, autophagy, angiogenesis and metabolic changes, 
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leading to inhibition of tumorigenesis (Figure 7) (Vousden and Prives, 2009; Yamamoto 




    
Figure 7. p53 responses in mediating tumor suppression. p53 is a key tumor suppressor implicated in 
the regulation of cell survival, proliferation and apoptosis by the transcriptional activation of p53 target genes 
(from Bieging and Attardi, 2012). 
 
The discovery of vast and varied transcriptional targets controlled by p53 raises new 
questions about how these networks coordinate to promote tumor suppression. The 
activation of p53 efficiently inhibit cell proliferation and cancer development. This activation 
is driven by a diversification of stress signals that a cell might run into during cancer 
progression, like genotoxic damage, oncogene activation, loss of cell-cell contacts, 
hypoxia. But the mechanisms of action are more intricated. The p53 protein has a short 
half-life under normal conditions. Because of the negative effects of p53 on cell 
proliferation and growth, eukaryotic organisms have evolved a feedback autoregulation to 
maintain low levels of the protein, in the absence of cellular stress. The protagonists are 
two oncoproteins: MDM2 and MDMX (Khoo et al., 2014; Lu, 2017; Eischen, 2017; Zhou et 
al., 2017; Wiman, 2010). MDM2 is a RING finger-containing protein, encoded by a p53 
target gene, that utilizes several mechanisms to inhibit p53 activity. First, it possesses an 
intrinsic E3 ligase to mediate p53 polyubiquitination and proteasomal degradation (Wiman, 
2010). Also, it targets p53 for monoubiquitination and nuclear export, thus preventing it 
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from binding to its target promoters into nucleus (Li et al., 2003). Additionally, it inhibits p53 
by directly associating with and hiding the trans-activation domain (TA) (Oliner et al., 
1993). Lastly, it can suppress TP53 mRNA translation by promoting RPL26 degradation 
and dissociating the RPL26-p53 mRNA interaction (Ofir-Rosenfeld et al., 2008). MDMX, 
an MDM2 homologue without any apparent intrinsic E3 ligase activity, repress p53 activity 
partnering with MDM2 (Wade et al., 2013). It associates with MDM2 through their C-
terminal RING domains and drives the E3 ligase activity of the second towards p53. 
MDMX can also suppress p53 activity by directly interacting with the N-terminal TA domain 
(Badciong and Haas, 2002). This MDM2-MDMX-p53 loop is critically important for normal 
growing of cells but is often hijacked by cancer cells for their growth benefits. Several type 
of cancers express high levels of MDM2 and/or MDMX that inactivate p53 and its 
downstream pathways (Zhou et al., 2017; Wiman, 2010). Like most transcription factors, 
p53 contains distinct domains responsible for sequence-specific DNA binding and 
transcriptional activation. The DNA binding domain comprises residues 100–300 and 
directs p53 to p53-response elements (p53 RE). The DNA binding domain is the most 
common site for mutations in cancer (Brosh and Rotter, 2009), underscoring the 
importance of p53 DNA binding function for tumor suppression. Two distinct transcriptional 
activation domains (TADs), spanning residues 1–40 and 40–83, cooperate for full p53 
transactivation capacity. These domains were defined initially by their ability to confer 
activation potential on a Gal4 DNA binding domain in reporter assays, and residues within 
these domains critical for transactivation were pinpointed through additional reporter 
assays (Venot et al., 1999). Recently, the specific contributions of each domain to various 
p53 functions in vivo have been clarified through the generation of TAD mutant knock-in 
mice, and we now appreciate that the TADs are differentially required for the activation of 
distinct sets of p53 target genes and for different biological functions (Johnson et al., 2005; 
Brady et al., 2011). This knowledge can now be harnessed to map the transcriptional 
networks critical for p53 function in tumor suppression. 
 
1.3.3.1 Mutant p53 in cancer 
Perturbations in p53 signaling pathways are believed to be required for the development of 
many cancers. The significance of p53 in tumor suppression in humans is highlighted by 
its inactivation in over half of all human cancers. Unlike wild-type p53, which under normal 
conditions has a short half-life curtailed when it is targeted by MDM2 for degradation, 
mutant p53 proteins are outside this negative feedback loop and accumulate to high levels 
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in cancer cells. Alterations in this gene have been found in every region, but only few of 
the most frequently occurring mutations have been studied. In some cases, frameshift or 
non-sense mutations result in loss of p53 protein expression and function (LOF), however, 
more frequently, alterations in p53 result in missense mutations, with the substitution of a 
single amino-acid that can be stably expressed in the tumor cell. These substitutions occur 
through the entire gene, but mostly accumulate in the DNA-biding domain of p53, affecting 
six hot-spot residues (R175, G245, R248, R249, R273, R282) of the protein translating 
into various impact on its structure‐ function activity (Figure 8). Moreover, categorized into 
structural (R175, G245, R249, R282) and contact (R248 and R273) mutations with effects 




Figure 8. The TP53 hot-spot mutations. p53 contains a natively unfolded amino-terminal transactivation 
domain (TAD), followed by a proline-rich region (PRR). The structured DNA-binding and tetramerization 
domains (OD) are connected through a flexible linker region. Similarly to the TAD region, the regulatory 
domain at the extreme carboxyl terminus (CTD) is also intrinsically disordered. The vertical bars indicate the 
relative missense-mutation frequency in human cancer for each residue based on the TP53 Mutation 
Database of the International Agency for Research on Cancer (www-p53.iarc.fr), showing that most cancer 
mutations are located in the DNA-binding domain (from Joerger and Fersht, 2010).  
 
These conformational alterations disrupt its function as a transcription factor in recognizing 
its DNA targets thereby inactivating its tumor suppressor activity (Muller and Vousden, 
2014; Olotu and Soliman, 2017). This classification is an over-simplification, because 
different mutations can lead to different alterations in the structure and conformational 
stability of the p53 protein. Notably, not only the position of the mutation, but also the 
nature of the substitution may influence the activity of the resulting mutant protein 
(Brachova et al., 2013). 
p53 contact with the DNA's major and minor groove is at the loop-sheet-helix-motif 
conserved residues and R248 of the L3 (large loop), respectively (Joerger and Fersht, 
2007). Moreover, p53 contact and structural mutations affect its DNA interaction both 
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directly and indirectly by perturbing the conformation of the binding surface thereby 
prompting its transition from the folded active wild-type state to an unfolded non-active 
state. Restoration of DNA binding has, therefore, been the subject of interest in most 
mutant p53 translational research with the design of reactivators, which are able to interact 
with p53 mutants and restore its wild-type transcriptional activities. Mutants displays 
structural distortion, reduction in flexibility and increase in rigidity hence its kinetic stability 
(Olotu and Soliman, 2017). However, some of these variants not only lose their tumor-
suppressive capacity, but also enrich cells with oncogenic gain-of-function (GOF) 
properties, like enhanced proliferation, invasion and migration, genomic instability and 
resistance to chemotherapy, that contribute to tumor aggressiveness (Oren and Rotter, 
2010). Therefore, distinct p53 mutations could display variable transactivation capacity 
towards different target sequences, affecting distinct cellular pathways (Variant-specific 
effects) (Kato et al., 2003). Furthermore, different p53 mutants may also possess a set of 




Figure 9. Mutant p53 gain-of-function effects. Different mutant p53 gain-of-function could have Pan-
mutant effects, shared among all the mutants, or Variant-specific effects, for which every mutant has single 
specific targets (adapted from Oren and Kotler, 2016). 
 
So the identification of common pan-mutant mechanisms of action, shared by most of 
cancer-associated p53 mutants, is very attractive, especially if those mechanisms can be 
targetable by specific drugs (Oren and Kotler, 2016; Girardini et al., 2011; Muller et al., 
2011). This approace is considered more workable than targeting mutant p53, which lacks 
a well-defined common site for binding reactivating small molecules, and presents 
structural heterogeneities induced by specific mutations (Wiman, 2010). 
 
Pan-mutant effects Variant-specific effects
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Aim of the study 
 
 
Improving response to platinum-based agents represents an unmet goal in EOC 
treatment. Few models of isogenic ovarian cancer platinum resistant cell lines exist. 
Therefore, we contributed to this issue selecting and characterizing three isogenic 
platinum resistant cell lines (MDAH-2774, TOV-112D and OVSAHO) to study and 
understand the molecular mechanisms at the basis of the onset of acquired resistance to 
platinum. This approach suggests new possible strategies to overcome resistance and 
represents a very relevant topic in ovarian cancer research. Moreover, the characterization 
of MDAH-2774 PT-res cells underlined the link between p53 mutational status and 
regulation of mitosis, suggesting their role in the acquisition of novel cellular phenotypes at 



























3.1 Generation of cisplatin resistant cell lines 
We have contributed to understand the mechanisms underlying acquired platinum 
resistance, through the selection of seven new models of platinum resistant isogenic EOC 
cell lines encompassing the principal EOC histotypes as defined by published results 
(Domcke et al., 2013; Beaufort et al., 2014; Dai et al., 2009; Sonego et al., 2017). In 
particular we selected: MDAH-2774 (hereafter referred as MDAH) and TOV-112D as 
models of high grade endometrioid cancer; OVSAHO and OVCAR-8 as models of high 
grade serous-carcinomas; SKOV-3 cell line is frequently cited as “serous”, but it is better to 
report it as “adenocarcinoma cell line derived from the ascitic fluid”; TOV-21G and ES-2 as 
models of clear-cell ovarian carcinomas.  
First, we treated cells with increasing concentrations of cisplatin (CDDP) for 72 hours and 
established the cisplatin concentration to obtain 50% of cell death (IC50) of the different 
cell lines. All these cell lines can be considered cisplatin sensitive with a platinum IC50 




Figure 10. IC50 of parental EOC cells treated with cisplatin (CDDP). EOC cells were treated with 
increasing doses of CDDP for 72 hours to evaluate their cisplatin IC50. EOC cell lines can be considered 
cisplatin sensitive. Data are expressed as the mean (±SD) of percentage of viable cells respect to untreated 
cells (n=3 biological replicates each performed in triplicate).  
Cisplatin resistant EOC cell lines were generated using the “pulse” method (Figure 11), 
that has been considered the most appropriate strategy to generate drug resistant ovarian 
cancer cells in vitro, since it is similar to that used in the clinic with pulse dosage according 
to plasma peak concentration in patients (Yan et al., 2007). However, using this approach 
we were not able to select SKOV-3, OVCAR-8 and ES-2 cell lines. Thus, we used another 
method, the low-dosage intermittent one, that we called “incremental” method, increasing 
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the dose every 5 treatments (Figure 11) (Yan et al., 2007). As shown in Figure 11, cells 
were plated at high confluence (step 1) and treated for 2 hours with a CDDP dose 10-fold 
higher than their calculated IC50 (“pulse method”) (step 2) or for 48 hours with a low dose 
of CDDP (“incremental method”). After a recover period (step 3), “resistant” cells were 
subjected again to step 1-3 for additional 20 cycles (Figure 11). By performing this 
schedule of cisplatin treatments, we selected two different CDDP resistant populations 




Figure 11. Generation of cisplatin resistant cell lines. Experimental design used to select cisplatin 
resistant (PT-res) cells. Cells were plated at high confluence (step 1) and treated for 2 hours with a cisplatin 
dose 10-fold higher than their calculated IC50 (“pulse method” or for 48 hours with  a low dose of CDDP 
(“incremental method”) (step 2). After a recover period (step 3), “survived” cells were subjected again to step 
1-3 for additional 20 cycles, and then their cisplatin sensitivity tested again. Adapted from Sonego et al., 
2017.  
 
After 20 cycles of treatment, we tested again the CDDP sensitivity of the resulting cells. 
PT-res cells displayed a CDDP IC50 3- to 5-fold higher than parental cells (Figure 12). We 
experimentally verified that the resistant phenotype was stable and maintained 
independently from the presence of CDDP in the culture medium. 
In this work is presented only the characterization of the first three cisplatin resistant cell 
lines generated: MDAH, TOV-112D and OVSAHO. 
Even in this simplified model system, it was clear that CDDP resistance is a multifactorial 
phenotype associated with the development of numerous resistance mechanisms. It is well 
accepted that ovarian cancers, that become resistant to aggressive cisplatin-based 
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Figure 12. Dose-response curves of parental and PT-res cells. (A) Cisplatin dose response curves of 
parental and PT-res cells. Results are expressed as percentage of viable cells respect to untreated cells. 
IC50 (half maximal inhibitory concentrations) are reported (n  =  3 biological replicates each performed in 
triplicate). Statistical significance was determined by repeated-measures analysis of ANOVA test 
(*p  <  0.05; **p  <  0.01; ***p  <  0.001; ns  =  not significant). Graphs of the first 3 cell lines used, taken 
as an example; (B) in the table all the cell lines. Adapted from Sonego et al., 2017. 
 
For these reasons we tested if PT-res cells acquired cross-resistance to Taxol and 
Doxorubicin, two other chemotherapeutic drugs commonly used to treat EOC patients. 
MDAH and OVSAHO, but not TOV-112D, PT-res cells displayed an IC50 for Taxol of 2- to 
5-fold higher than parental cells (Figure 13A). In the case of Doxorubicin, MDAH and TOV-
112D, but not OVSAHO, PT-res cells were more resistant than parental cells (Figure 13B). 
 
3.2 Cell cycle progression of cisplatin resistant cells 
We next checked if this PT-resistant phenotype was linked to an altered cell cycle 
progression. We performed FACS analyses of DNA content under basal conditions and we 
observed that PT-res cells did not highlight any significant variation in cell cycle distribution 
compared to parental ones (Figure 14A). This result was confirmed by 
immunofluorescence analyses of phosphorylated Histone H3, a marker of mitotic cells, 
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showing no differences in the percentage of pH3 positive cells (mitotic index) of parental 
and PT-res cells (Figure 14B). 
 
 
Figure 13. Dose-response curves of parental and PT-res cells. Taxol (A) and Doxorubicin (B) dose 
response curves of parental and PT-res cells. Results are expressed as percentage of viable cells respect to 
untreated cells. IC50 (half maximal inhibitory concentrations) are reported (n  =  3 biological replicates each 
performed in triplicate). In the lower table, the IC50 calculated for each drug and cell line is shown. In figure 
the difference between parental cells and each PT-res pool is reported. Statistical significance was 
determined by repeated-measures analysis of ANOVA test (*p  <  0.05; **p  <  0.01; ***p  <  0.001; 
ns  =  not significant). Adapted from Sonego et al., 2017. 
 
3.3 Morphology and adhesion ability of cisplatin resistant cells 
A key change associated with the cisplatin resistant phenotype was a clear alteration of 
PT-res cells morphology, respect to parental cells (Figure 15). Parental TOV-112D cells 
are small and comprise both rounded and spindled-shaped cells, while the correspondent 
PT-res cells were frankly polygonal. Conversely, MDAH cells are large epithelial-like cells 
and the correspondent resistant ones displayed a significantly tapered shape. Finally, 
OVSAHO parental cells are small round-shaped cells growing in small epithelial-like islets, 






Figure 14. Cell cycle distribution of cisplatin resistant cells. (A) FACS analyses of DNA content of 
parental and PT-res cells in exponentially growing conditions. Parental and PT-res cells show a similar cell 
cycle progression. (B) Evaluation of mitotic index of parental and PT-res cells in exponentially growing 
conditions. Mitotic index was calculated by immunofluorescence analyses, using the expression of pS10-H3 
as a marker of mitotic cells. Data are expressed as percentage of pH3-positive cells. Statistical significance 







Figure 15. PT-res cells show an altered cell morphology. Representative phase-contrast 
photomicrographs of EOC parental (top) and PT-res (middle and bottom) cells in exponential phase (20X, 
original magnification). Adapted from Sonego et al., 2017. 
 
We observed that all PT-res cells avoided the formation of an uniform monolayer, also 
when plated at high density (Figure 15). These morphological modifications suggested that 
the balance between epithelial and mesenchymal status could be altered in PT-res cells, 
possibly through alteration of the Epithelial-Mesenchymal Transition (EMT) and/or 
Mesenchymal-Epithelial Transition (MET) processes. It has been proposed in EOC that an 
EMT-like process, characterized by alternation of EMT and MET, could confer the ability to 
spread, attach and grow in the peritoneal lining and, eventually, favour the appearance of 
chemoresistant clones (Ahmed et al., 2010). To verify this hypothesis in our models, we 
tested the expression of known modulators of EMT and MET, like ZEB-1, SNAIL, SLUG 
and TWIST-1, by Western Blot analysis. The results of our analysis showed changes, that 
were essentially cell line specific, in the expression of the tested transcription factors in 
PT-res cells. Specifically, OVSAHO cells showed an increase of ZEB-1 protein while TOV-
112D PT-res cells had increased levels of SNAIL and TWIST-1 compared to parental cells 
(Figure 16). Minor changes were observed in MDAH cells with only a slight increase in 
SNAIL expression in PT-res cells (Figure 16). These data suggest that an altered balance 
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Figure 16. Western Blot analysis of EMT/MET markers expression in parental and PT-res cells. The 
expression levels of ZEB-1, Snail, Slug and Twist-1 in parental and PT-res cells. GAPDH was used as 
loading control. PT-res cells showed an altered expression of these EMT/MET markers respect to parental 
cells. P= parental cells; #1 and #2= the two PT-res populations. Adapted from Sonego et al., 2017. 
 
Using immunofluorescence analyses we evaluated the expression and distribution of 
defined markers of cytoskeleton organization and cell-cell junctions, including F-actin, α-
tubulin, ZO-1 (marker of tight junctions) and γ-catenin (marker of adherens junctions). The 
obtained result confirmed that PT-res cells displayed a different organization of actin and 
microtubular cytoskeleton, with respect to their parental counterparts, showing a more 




Figure 17. PT-res cells fail cytoskeleton organization. (A) Representative images of parental and PT-res 
cells, immunostained for the expression and localization of α-tubulin (green), ZO-1 (red) and F-Actin (blue), 
are reported. Scale bar  =  25  µm. Adapted from Sonego et al., 2017. 
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Importantly, PT-res cells failed to form well-organized cell-cell junctions, as demonstrated 
by ZO-1 and γ-catenin redistribution in the cytosol rather than at the cell membrane, and 
by the fact that ZO-1 and γ-catenin failed to properly locate at the cell-cell contacts, as 
observed in parental cells (Figure 18).  
 
 
Figure 18. PT-res cells show non-organized cell-cell junctions. Representative images of γ-catenin 
(green) and ZO-1 (red) in parental and PT-res cells cultured in exponentially growing conditions. Nuclei are 
in blue. Scale bar  =  25  µm. Adapted from Sonego et al., 2017. 
 
Mesothelial cells represent the cellular component on which platinum resistant EOC cells 
attach and grow in vivo, when spreading from the primary lesions. Since PT-res cells 
seemed to display an altered balance between epithelial and mesenchymal status and a 
disorganization in the space-growth, we tested the growth of parental and PT-res cells on 
a mesothelial cell layer. To this aim, parental and PT-res EOC cells were labeled with the 
lipophilic green fluorescent dye, DiO, and then seeded on a mesothelial cell layer allowing 
to attach and grow for 24  hours. The DiO lipophilic tracer is in fact used in several 
biological assays to characterize the behaviour of a difend cell population including 
detection of cell-cell fusion and cell adhesion, tracing of migrating cells, labeling of 
lipoproteins, etc (Spötl et al., 1995; Bastiat et al., 2013; Huerta et al., 2006). Using this 
assay coupled with immunofluorescence and confocal microscopy we observed that all 
PT-res cells adhered and grew on the mesothelium at higher rate than the parental ones 
(Figure 19A). Three-dimensional reconstruction of the fields (Figure 19B) and 
representative XY planes of confocal images (Figure 19C) confirmed and reinforced the 
obtained result that is consistent with an increased ability to disseminate in the peritoneal 






Figure 19. PT-res cells growth on a mesothelial cell layer. (A) Maximal projections of images of parental 
and PT-res cells labeled with the green fluorescent marker DiO (green) and cultured on a monolayer of 
mesothelial cells for 24  hours. Cells were then fixed and stained with Phalloidin (F-Actin, red) and TO-PRO-
3 (nuclei, blue). In the right graph, the number (mean  ±  SD) of cancer cells/field is reported. Statistical 
significance was determined by a two-tailed, unpaired Student’s t-test (*p  <  0.05 and **p  <  0.01) 
(PT#2  =  PT-res#2). (B) 3D reconstruction of confocal stack images of DiO-labeled parental and PT-res 
cells (green) cultured on a monolayer of mesothelial cells for 24 hours in the absence of serum. Cells were 
then fixed and stained with Phalloidin (F-Actin, red) and TO-PRO-3 (nuclei, blue). 
(C) Representative XY planes of confocal images of parental and PT-res cells labeled as in B. YZ and XZ 
projections show the contacts between mesothelial (well flat and delineated by red F-actin) and EOC cells 
(“spheric” and green labeled). B and C are projections of the images reported in (A). Adapted from Sonego 
et al., 2017. 
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3.4 Response to cisplatin-induced damage of PT-res cells 
 
We next investigated the response of parental and PT-res EOC cells to cisplatin treatment 
looking at the appearance of DNA damages and at the resolution of DNA platination. To 
this aim, cells were treated with cisplatin (50 M) for 16 or 24 hours, the phosphorylation 
levels of Histone H2AX (Ser 139) (H2AX), a well-known marker of damaged DNA, were 
evaluated by Western Blot analyses. In all tested models, PT-res cells showed a reduced 
expression of H2AX indicating that they accumulated less DNA damage (Figure 20A). 
Accordingly, using a specific anti cisplatin-DNA adducts antibody in dot blot analyses, we 
observed a reduced DNA platination after CDDP exposure, more evident after 24 hours of 
treatment, followed by a faster removal of platinum from the DNA, already resolved after 




Figure 20. PT-res cells accumulate less DNA damage after cisplatin treatment. (A) Western blot 
analyses of Ser 139 phosphorylated Histone H2AX (γH2AX) expression, used as marker of DNA damage, in 
parental and PT-res cells untreated (0) or treated with cisplatin for 16 and 24  hours, as indicated. Vinculin 
was used as loading control. (B) Dot blot analyses evaluating the amount of platinated-DNA in parental and 
PT-res cells untreated (NT) or treated with cisplatin for 16 and 24  hours and then released in cisplatin-free 
medium for additional 24 (+24) or 48 (+48) hours to allow for DNA repair. Adapted from Sonego et al., 2017. 
 
Based on these results, we next compared the cell cycle distribution of PT-res cells and 
parental ones under cisplatin treatment for 16 and 24 hours and after treatment removal 
for additional 24 hours. The data collected in the TOV-112D model, showed that parental 
cells exposed to cisplatin remained blocked in their cell cycle distribution and started 
undergo apoptosis (sub-G1 population) 24 hours after the somministration of treatment 
and failed to reenter the cell cycle up to 24 hours after the removal of the drug. 
Conversely, PT-res cells were resistant to platinum-induced apoptosis and were able to 
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resolve the cisplatin-induced cell cycle block, massively restarting to recycle within 8 hours 
from the drug release (Figure 21). Similar results were observed using both MDAH and 
OVSAHO models, overall suggesting that PT-res cells are more prone to bypass the cell 
cycle arrest induced by platinum treatment.  
 
3.5 PT-res cells are characterized by cell-specific alterations of cisplatin 
transporters 
The above results showing reduced DNA platination and DNA damage response and 
faster resolution of cisplatin-induced cell cycle block, suggested that PT-res cells could 
have acquired defects in the uptake and/or efflux of cisplatin into/from the cell. The 
cisplatin influx into cells is mainly regulated by the copper transporter CTR1, while the 
cisplatin efflux from the cells is mediated mainly by MDR1, ATP7A and ATP7B 
transporters. CTR2 is a copper uptake protein substantially homologous to CTR1, but it 
plays an opposite role in platinum drugs transport (Galluzzi et al., 2014; Blair et al., 2010). 
Through qRT-PCR analyses we confirmed that all PT-res cells displayed a deregulation in 
the expression of the known cisplatin transporters CTR1, CTR2, MDR1, and/or ATP7A, 
although not in a common way. A significant decreased expression of CTR1 (Figure 22A), 
that could be responsible of a reduction in cisplatin influx, was observed in MDAH and 
TOV-112D PT-res respect to parental cells together with an upregulated expression of 
MDR1 gene (Figure 22B), that controls the efflux of cisplatin from the cell. On the contrary, 
these cells displayed a more or less downregulation of the efflux transporters ATP7A/B, 
and a non univocal variation in CTR2 (Figure 22B), suggesting that they more likely rely on 
the overexpression of MDR1 to excrete the drug. OVSAHO PT-res cells, instead, 
expressed similar amount of MDR1, but strongly increased the expression of ATP7A, 
ATP7B and CTR2 (Figure 22B) respect to parental cells. Unexpectedly, they showed an 
upregulated expression of the influx transporter CTR1. Taken together, these data suggest 
that all PT-res cell lines commonly displayed a deregulation in platinum transport that, 




Figure 21. Cell cycle distribution of PT-res cells under cisplatin treatment and during drug release. 
(A) FACS analyses of DNA content in TOV-112D parental and PT-res cells untreated (NT) or treated with 
cisplatin for 16 and 24  hours and then released in cisplatin-free medium for additional 4, 8 or 24  hours, as 
indicated. A typical histogram for each cell line is shown and the correspondent cell cycle distribution 
(mean  ±  SD n  =  3 biological replicates) is reported in the right tables. (B-C) FACS analyses of DNA 
content in MDAH and OVSAHO parental and PT-res cells untreated (NT) or treated with cisplatin for 
24  hours and then released in cisplatin-free medium for additional 8 or 24  hours, as indicated. A typical 
histogram for each cell line is shown and the correspondent cell cycle distribution (mean  ±  SD n  =  3 









Figure 22. mRNA expression levels of cisplatin transporters in parental and PT-res cells. (A) Graphs 
showing the expression of CTR1 influx cisplatin-transporter in the indicated cell lines, evaluated by qRT-PCR 
analyses. mRNA levels was analyzed in triplicate and normalized using SDHA housekeeping gene. Data 
represent the mean  ±  SD of 3 biological replicates, performed in duplicate. Statistical significance was 
determined by a two-tailed, unpaired Student’s t-test (ns  =  Not Significant, *p  <  0.05, **p  <  0.01, 
***p  <  0.001). (B) Graphs showing the expression of MDR1, ATP7A, ATP7B and CTR2 efflux cisplatin-
transporters in the indicated cell lines, evaluated by qRT-PCR analyses. mRNA levels was analyzed in 
triplicate and normalized using SDHA housekeeping gene. Data represent the mean  ±  SD of 3 biological 
replicates, performed in duplicate. Statistical significance was determined by a two-tailed, unpaired Student’s 
t-test (ns  =  Not Significant, *p  <  0.05, **p  <  0.01, ***p  <  0.001). Adapted from Sonego et al., 2017. 
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3.6 MDAH PT-res cells grow slower than their parental counterpart, giving rise to 
large, multinucleated cells 
When we analyzed the cell cycle progression pattern between parental and PT-res cells in 
exponentially growing conditions (DNA content in FACS analysis Figure 21), we did not 
observe alterations in cell cycle phases distribution, nevertheless MDAH PT-res cells 
presented an impaired growth rate (Figure 23). This phenotype was not observed in the 
two other isogenic cell lines (Figure 23).  
 
 
Figure 23. MDAH PT-res cells show an impaired growth rate. Growth curve analysis of parental and PT-
res cells. Viable cells were counted daily in triplicate for 5 days, by trypan-blue dye exclusion method. Data 
are expressed as fold increase respect to day 0. Statistical significance was determined by two-way ANOVA 
test (*p < 0.05 and **p < 0.01 and ***p < 0.001).  
 
We thus tested if the reduction in cell growth could be due to a different mechanism. 
Interestingly, a closer examination of MDAH cells by transmission microscopy (Figure 24A) 
and immunofluorescence analyses (Figure 24B) showed only in PT-res pools, but not in 
parental cells, the presence of large, frequently multinucleated cells that were often 
positive for the apoptotic marker cleaved caspase 3 (CC3).  
 
3.7 Selection of MDAH PT-res single clones 
To better characterize this phenotype, we performed a single cell cloning (Figure 25A) of 
PT-res cell pools. We isolated twenty-three PT-res single-cell clones from the two resistant 
PT-res pools (eleven from PT-res#1 and twelve from PT-res#2) and confirmed that all of 
them were platinum resistant. Among these, we randomly selected 4 PT-res clones for a 
more complete characterization. Kill-curve analyses performed treating parental e PT-res 
cells with increasing doses of CDDP for 72 hours, demonstrated that PT-res clones have a 
CDDP IC50 from 2.5 to 6.7 folds higher than the one of parental cells (Figure 25B), and 
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Figure 24. MDAH PT-res cells present a subpopulation of enlarged cells. (A) Representative phase-
contrast photomicrographs of MDAH parental and PT-res pools in exponential growth phase (20X, original 
magnification). Scale bar = 25 μm. White arrows point to possible MultiNucleated Giant Cells (MNGC) here 
defined as cells with a cell area 1.5 fold bigger than the mean cell area of parental MDAH cells, as calculated 
using the ImageJ software. The percentage of MNGC in each cell line is reported under the respective 
images (at least 50 cells were analyzed for each cell line). (B) Representative images of Cleaved Caspase 3 
(CC3) (green) in MDAH parental and PT-res cells cultured in exponentially growing conditions. Nuclei are in 
blue. Scale bar = 33 μm. On the right the graph reports the number (mean ± SD) of CC3 positive cells/field is 
reported. Statistical significance was determined by unpaired Student’s t-test (*p < 0.05 and **p < 0.01 and 
***p < 0.001). Adapted from Lorenzon et al., 2020. 
 












Figure 25. MDAH PT-res single cell cloning. (A) Experimental design used to select PT-res single clones. 
MDAH PT-res cells were harvested, counted (step 1) and plated 0.7 cells/well in 96wells plates (step 2). 
After a recover period, single cells started to grow and were amplified (step 3) to test cisplatin resistance. (B) 
Nonlinear regression analyses of cell viability assay of MDAH parental and PT-res single cell clones treated 
with increasing doses of CDDP for 72 hours. Data are expressed as percentage of viable cells respect to the 
untreated cells and represent the mean (±SD) of 3 biological replicates. The table on the right reports the 
IC50 and the confidence interval (C.I.) of each cell population. Fisher’s exact test was used to calculate the 
global  p-value reported in the graph. Adapted from Lorenzon et al., 2020. 
 
We next evaluated their growth rate by growth curve analyses and we observed that, as 
PT-res pools #1 and #2, also the four PT-res clones tested had an impaired growth rate 
when compared to parental cells (Figure 26A). Intriguingly, MDAH PT-res cell clones also 
contained a subpopulation of larger multinucleated cells not present in parental cells, here 
defined as cells with a cell area 1.5 fold bigger than the mean cell area of parental cells 
(Figure 26B). 
 
















































Figure 26. PT-res clones also show an impaired growth rate and the presence of enlarged cells. (A) 
Growth curve analysis of parental and PT-res clones. PT-res clones (#12, #19, #42 and #51) were seeded in 
sextuplicate in 96-well plates and cell proliferation was determined daily (for 5 days) by MTS assay using the 
CellTiter 96 AQueous cell proliferation assay kit (Promega). Statistical significance was determined by two-
way ANOVA test, p-value reported in the graph (*p < 0.05 and **p < 0.01 and ***p < 0.001). (B) 
Representative phase-contrast photomicrographs of MDAH parental and PT-res clones in exponential 
growth phase (20X, original magnification). Scale bar = 25 μm. The graph reports the cell area (mean  SD) 
expressed as arbitrary units (A.U.). A threshold has been established (dash line) to determine the 
percentage of MNGCs cells here defined as cells with a cell area 1.5 fold bigger than the mean cell area of 
parental MDAH cells. The quantification of MNGCs is reported under the graph as % of analyzed cells. 
Statistical significance was determined by one-way ANOVA test, global p-value < 0.0001; a multiple 
comparison analysis was done to determine significant differences among groups (*p < 0.05 and **p < 0.01 
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Since our previous results with MDAH PT-res pools demonstrated no differences in cell 
cycle distribution between parental and PT-res pools under exponentially growing 
conditions, we decided to investigate if an alteration in cell cycle progression could be 




Figure 27. PT-res clones shows a similar cell cycle progression pattern. FACS analyses of DNA 
content of MDAH parental and PT-res clones in exponentially growing conditions. The plots overlapping 
show the cell cycle distribution of each cell line. The propidium iodide (PI) stained cells were recorded by BD 
FACScan or BD FACSCalibur flow cytometer. The right table reports the cells percentage in G1, S or 
G2/M phases. Adapted from Lorenzon et al., 2020. 
 
Cell cycle progression in exponentially growing cells showed small differences between 
parental and PT-res clones that displayed a slight increase in G2/M population and a low 
decrease in S phase cells, once compared to parental ones (Figure 27). To better study 
cell cycle progression and trying to force the system allowing cells to complete one mitotic 
division, we decided to use cell synchronization. To this aim parental and PT-res clones 
#12 and #42 were synchronized at the G1/S phase boundry by double thymidine block. 
After release into normal medium, cells were collected at different time points (i.e. 12, 16 
and 24 hours), lysated and evaluated by Western Blot analyses for the expression of 
defined and accepted molecular makers of the different phases of the cell cycle. The 
results of this analysis were quite striking and informative showing that, while the 
phosphorylation of pRB (Ser780) (G1/S phase marker) and the expression of Cyclin A (S 
phase marker) and Cyclin B1 (G2/M marker) were equally regulated in parental and PT-
res clones (Figure 28A, first, second and third blot lanes), PT-res cell clones displayed an 
earlier and prolonged phosphorylation of Histone H3 (pH3 Ser10), a recognized marker of 
M phase, accompanied by a higher expression of the inhibitory phosphorylation of CDK1 
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(Tyr15) a serine/threonine kinase that is a key player in M phase entry and progression 
(Figure 28A, forth and sixth blot lanes). These data suggested that MDAH PT-res cells 
likely had an alteration in M phase progression that indeed could explain the higher 
number of multinucleated cells. Based on these results, we next quantified the number of 
pH3 Ser10 positive cells by immunofluorescence analyses (Figure 28B), in cell 
synchronized by serum starvation for 72 hours and then released in complete medium for 
additional 24 hours. This approach allowed to exclude that differences observed in 
Western Blot analyses were due or enhanced by the use of the double thymidine block. 
Results showed that all four PT-res clones had a significanlty increased number of pH3 
Ser10 positive mitotic cells/field (Figure 28C).  
FACS analyses of DNA content of synchronized cells (Figure 29A) confirmed, in the PT-
res clones, the persistence of an increased G2/M population 24h after release from double 
thymidine block, compatible with the observed increased expression of mitotic markers 
(Figure 28A). This analysis combined with an immunofluorescence one also revealed and 
confirmed that PT-res clones had an increased number of multinucleated cells with high 
DNA content (Figure 29B and 30). The quantification of multinucleated cells/field 
evidenced significant differences for all clones respect to parental cells and no significant 












          
 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
Figure 28. MDAH PT-res clones display a mitotic defect that could explain the presence of the 
enlarged subpopulation. (A) Western Blot analysis of MDAH parental and PT-res clones (#12 and #42) 
synchronized by double thymidine block and released for the indicated hours (hrs). The indicated cell cycle 
markers were analyzed. GAPDH was used as loading control. (B) Representative images of parental and 
PT-res single clones, immunostained for pH3 (green), -tubulin (red) and TO-PRO-3 (nuclei, blue) are 
reported. White arrows indicate pH3-positive mitotic cells. Scale bar = 44 μm. (C) The graph reported the 
number (mean ± SD) of mitotic cells/field. Each dot corresponds to one field, at least 10 fields were scored 
for each cell line. Statistical significance was determined by a two-tailed unpaired Student’s t-test (*p < 0.05 
and **p < 0.01 and ***p < 0.001). Adapted from Lorenzon et al., 2020. 
 
Based on the notion that multinucleated cells could derived from an altered mitotic division, 
we studied more in detail the morphology of mitotic cells in parental and PT-res clones 
using immunofluorescence analyses coupled with confocal analyses, and staining cells for 
-tubulin, an accepted centrosome marker, -tubulin to evidence the mitotic spindle, and 
TO-PRO-3 for DNA staining (Figure 31A). These analyses demonstrated that PT-res 
clones, when compared to parental cells, presented an increased number of aberrant 
mitotic cells (Figure 31B), that represent more than 50% of all scored mitosis (Figure 31C). 
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Figure 29. (A) FACS analyses of DNA content of MDAH parental and PT-res clones (#12 and #42) 
synchronized by double thymidine block and then released in thymidine free medium for the indicated hours. 
The histogram overlay shows the cell cycle distribution of each cell line at the different time points, as 
indicated by the color code. The bottom tables report the cells percentage in G1, S or G2/M phases. (B) 
FACS analyses of MDAH parental and PT-res clone 42 cells evaluating the size and the cell cycle 
distribution of analyzed living cells. The left panels show cell size as determined by forward and side scatter 
fluorescence. The right panels show the DNA content distribution evaluated by the analyses of PI 
fluorescence read as FL2-Width and FL2-Area. In blue (P3) is highlighted the cycling population analyzed in 
the histograms reported in (A). In green (P2) is highlighted the giant cells population which also shows a 
DNA content >2n. The percentage of P2 cells is reported in plots. In red are marked dead cells or cells that 







Figure 30. PT-res clones are characterized by a high number of multinucleated cells. Representative 
images of MDAH parental and PT-res clones stained for F-actin with Phalloidin (F-actin, red). Nuclei are 
pseudo colored in blue (TO-PRO-3). In the lower magnifications white arrows indicate multinucleated cells. 
Scale bar = 44 μm. On the bottom, the number of multinucleated cells/field is reported (mean ± SD). 
Statistical significance was determined by a two-tailed unpaired Student’s t-test (*p < 0.05 and **p < 0.01 
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Figure 31. PT-res clones presented an increased number of aberrant mitotic cells. (A) Representative 
images of MDAH parental and PT-res clones, stained for α-tubulin (green), -tubulin (red) and TO-PRO-3 
(nuclei, blue). Scale bar = 44 μm. In the lower magnifications white arrows indicate mitotic cells. Scale bar = 
11 μm. (B) On the bottom-left, the graph reports the number of aberrant mitosis/field (mean ± SD). Statistical 
significance was determined by a two-tailed unpaired Student’s t-test (*p < 0.05 and **p < 0.01 and ***p < 
0.001). (C) The lower graph (right) reports the fraction of aberrant and normal mitosis expressed as 
percentage of total mitosis. Numbers above each column indicate the total number of mitosis analyzed for 
each cell type. Adapted from Lorenzon et al., 2020. 
 
Interestingly, as observed in PT-res pools, PT-res clones were more positive than parental 
cells for the expression of cleaved caspase 3 (Figure 32), and the increase in cleaved 







Figure 32. MDAH PT-res clones present an increased number of CC3 positive cells. Representative 
images of Cleaved Caspase 3 (CC3) (green) and α-tubulin (red) immunofluorescence staining in MDAH 
parental and PT-res clones in exponentially growing conditions. Nuclei are pseudo colored in blue (TO-PRO-
3). White arrows indicate CC3 positive cells.  Scale bar = 44 μm. The bottom graph reports the number 
(mean ± SD) of CC3 positive cells/field. Statistical significance was determined by a two-tailed unpaired 
Student’s t-test (*p < 0.05 and **p < 0.01 and ***p < 0.001). Adapted from Lorenzon et al., 2020. 
 
Overall the data collected so far suggested that defects in M phase progression 
accompanied the acquisition of the platinum resistant phenotype of MDAH cells, and likely 
resulted in an increased number of multinucleated giant cells (MNGCs) and an increase in 
cleaved caspase 3 positive cells. Both these phenotypes in turn could explain the lower 
growth rate of PT-res MDAH clones respect to the parental counterpart, without a clear 
evidence of cell distribution in the different phases of the cell cycle in FACS analyses, as 
reported previously (Figure 21). 
 
3.8 p53MUT downstream targets are differently modulated in PT-res clones 
A very recent report suggests that MNGCs could contribute to the chemoresistant 
phenotype of MDA-MB231 breast cancer cells, by increasing the production of Reactive 
Species of Oxygen (ROS) (Parekh et al., 2018). Accordingly, we showed that MDAH PT-





res clones presented a higher production of ROS than parental cells, both under basal 
conditions and after 24 hours of CDDP treatment (Figure 33), supporting the possibility 




Figure 33. ROS production in MDAH PT-res clones. Flow cytometry profiles of 2',7'-
dichlorodihydrofluorescein diacetate (H2-DCF-DA) fluorescence (FITC-A) used as an indicator for reactive 
oxygen species (ROS) generated in MDAH parental and PT-res clones, treated or not with cisplatin for 24 
hours. The emission wavelength (529 nm) was detected and recorded by BD FACSCanto II flow 
cytometer. The percentages of positive cells for oxidized H2-DCF-DA are indicated in the plots. Adapted 
from Lorenzon et al., 2020. 
 
Based on the above results, we tried to understand why MDAH PT-res cells acquired a 
MNGCs population and focused on the possible role of the tumor suppressor TP53, which 
plays a pivotal role in the control of M phase progression after therapy-induced DNA 
damage. Indeed, several reports suggest that cells lacking a functional TP53 enter mitosis 
even in the presence of a mutated DNA, especially when a mutated TP53 (p53MUT) is 















































cells lacking wild-type p53 functions escape cell cycle checkpoints and may undergo 
mitosis even after DNA damage and chromosomal aberrations, leading to the generation 
of MNGCs (Parekh et al., 2018; Lukin et al., 2015; Mirzayans et al., 2017). These 
evidences support the possibility that the presence of p53R273H in MDAH cells could be 
relevant for the onset, in MDAH PT-res cells, of the multinucleated phenotype. 
Interestingly, others and we demonstrated that p53MUT specifically regulates the 
expression of genes involved in the correct M phase progression and subsequent cell 
division (Girardini et al., 2011; Sonego et al., 2013; Mantovani et al., 2019). Our lab 
recently reported, in MDAH cells, that the proper expression, stability and activity of 
p53R273H, regulated by stathmin/ DNA-PKCS interaction, was necessary for the completion 
of a timely cell division and for the increased resistance to platinum-induced cell death via 
the regulation of several mitotic regulators like BUB1, CENPA, C21orf45 and NCAPH 
(Sonego et al., 2013); all belonging to the so-called p53MUT signature (Girardini et al., 
2011). For these reasons, we first analyzed the expression of the 10 genes belonging to 
this signature, in parental and PT-res clones. Among the tested genes, we observed a 
consistent increase in mRNA expression levels of CCNE2 and DEPDC1, and a decreased 
mRNA expression for NCAPH and C21orf45 in PT-res clones respect to parental cells 
(Figure 34A). On the other hand, no significant variations were detected in the mRNA 
expression of BUB1, CENPA, WDR67, CPSF6, FAM64A and EPB41, once compared PT-
res clones to parental counterpart, although a tendency for the overexpression of CENPA 
and CPSF6 was noted (Figure 34B). 
These alterations were also confirmed at protein level, by Western Blot analysis (Figure 
35). All these genes play a key role in mitotic cell division regulation: CCNE2 is linked to 
endoreplication and genomic instability (Caldon et al., 2013; Motwani and Schwartz, 
2000), C21orf45, also known as MIS18A, is a kinetocore protein belonging to the Mis18 
complex assembly that is crucial for CENPA deposition at the centromere (Pan et al., 
2017; Spiller et al., 2017), DEPDC1 is highly expressed in M phase and its silencing 
caused mitotic defects (Chen et al., 2017; Zhou et al., 2019) and NCAPH is a regulatory 
subunit of the condensin complex, required for the conversion of interphase chromatin into 
condensed chromosomes (Batty and Gerlich, 2019; Yin et al., 2017). Overall, their altered 
expression could participate to the development of an aberrant mitotic phenotype, like the 
one observed in our model. 
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Figure 34. mRNA expression levels of several genes belonging to the so-called p53MUT signature. (A) 
qRT-PCR analyses of the indicated genes in MDAH parental and PT-res clones. mRNA levels were 
analyzed in triplicate and normalized using GAPDH housekeeping gene. Data are expressed as fold of 
mRNA expression in PT-res cells respect to parental cells and represent the mean (± SD) of at least of three 
independent experiments. (B) qRT-PCR analyses evaluating the mRNA expression of the indicated p53MUT 
transcriptional target genes in parental and PT-res single clones. mRNA levels were analyzed in triplicate 
and normalized using GAPDH as housekeeping gene. Data are expressed as fold of mRNA expression in 
PT-res cells respect to parental one and represent the mean (± SD) of at least of three independent 
experiments. Statistical significance in (A) and (B) was determined by one-way ANOVA test; a multiple 
comparison analysis was done to determine significant differences among groups (*p < 0.05 and **p < 0.01 




Figure 35. Protein expression levels of genes found altered by qRT-PCR in MDAH PT-res clones. 
Western Blot analysis of NCAPH, DEPDC1, CCNE2 expression in parental and PT-res clones. GAPDH was 
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3.9 DNA-PKCS is not involved in the regulation of p53MUT activity in PT-res clones 
The collected data supported the possibility that MDAH PT-res clones displayed a different 
activity of p53MUT and, based on our previous results, suggested a role for DNA-PKCS/ 
stathmin in the regulation of p53MUT in EOC cells. First, we tested the expression of p53, 
stathmin and DNA-PKCS in PT-res clones and parental cells finding no significant changes 
in their expression levels, except for a slightly reduction of stathmin when assayed in 
exponentially growing conditions (Figure 36A). Considering that DNA-PKCS plays a major 
role in p53MUT regulation via phosphorylation of Ser 37, affecting its stability and/or its 
transcriptional activity (Sonego et al., 2013), we next checked p53 expression and 
phosphorylation levels in MDAH parental and PT-res cells, treated with high dose of CDDP 
for 16 hours and released in complete medium for 24 hours. All tested PT-res clones 
presented a higher phosphorylation of Ser37 and Ser15 of p53 respect to parental cells, 
both under platinum treatment and after the release, without significant changes in total 
protein levels. In the same settings, no differences in the expression of stathmin and DNA-
PKCS were observed (Figure 36B). 
 
     
 
Figure 36. The expression of p53, stathmin and DNA-PKCS in PT-res clones. (A) Western Blot analysis 
of DNA-PK, p53, stathmin expression in parental and PT-res clones. GAPDH was used as loading control. 
(B) Western Blot analysis of DNA-PK, phosphorylated p53 forms (Ser15 and Ser37), p53 and stathmin 
expression in parental and PT-res clones (#12 and #42), treated with CDDP for 16 hours and allowed to 
repair DNA for 24 hours (R24h). GAPDH was used as loading control. Adapted from Lorenzon et al., 2020. 
 
This increased phosphorylation was, however, not associated to an increased binding to 
DNA-PKCS (Figure 37A), neither to an increased p53MUT protein stability, at least in basal 
conditions. In fact, to determine the p53 protein half-life of MDAH parental and PT-res 
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cycloheximide (CHX). Cells treated with CHX for the indicated times were then lysated and 
cell lysated evaluated by Western Blot for the expression of p53. Densitometric analyses 
of the blots show that in parental and PT-res clones p53 had similar half life of about 12 






Figure 37. DNA-PKCS is not involved in the regulation of p53MUT activity in PT-res clones. (A) Co-IP 
analysis of endogenous DNA-PK and p53 proteins in parental and PT-res single clones (#12 and #42). Input 
shows the expression of the indicated proteins in the lysates used for IP experiments; IgG represents the 
control IP using an unrelated antibody. GAPDH was used as loading control. (B) Western blot analyses of 
p53 expression in parental and PT-res single clones (#12 and #42) treated with cycloheximide (CHX) for the 
indicated times. The graph reports the p53 expression as remaining fraction respect to T0 (mean ± SD of 3 
different experiments), normalized respect to GAPDH expression. Adapted from Lorenzon et al., 2020. 
 
3.10 MDAH PT-res clones gained a new TP53 missense mutation after therapy 
selection process 
To confirm the reported presence of p53R273H, we analyzed the complete coding sequence 
of TP53 from genomic DNA extracted from parental cells, PT-res pools and PT-res single 
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PT-res clones (and pools, data not shown) presented an additional mutation c.553A>G in 
exon 5, that determines a substitution of Serine residue in pos.185 to Glycine (p.S185G), 
that was not present in parental cells and that accompanied the p.R273H, c. 818G>A in 





Figure 38. MDAH PT-res clones gain a new TP53 missense mutation. Representative four-color 
fluorescence electropherograms of p53 Sanger sequencing (top) performed on parental and PT-res clones, 
black arrows indicate residues 273 and 185. Schematic diagram (bottom) of p53 gene (first) and protein 
(second). Exons are colour-coded according to the corresponding protein functional domains. Yellow dots 




































Therefore, we asked if this double mutant p53S185G/R273H could play a role in some of the 
biological characteristics observed in MDAH PT-res pools and clones described above. In 
order to verify this hypothesis, we silenced TP53 in both parental and PT-resistant clones 
and then treated cells with CDDP for 16h (Figure 39). 
 
 
Figure 39. Down modulation of p53 expression induces cell death. (A) Dose-response curves of MDAH 
parental and PT-res single cell clones, transduced with sh-ctrl or sh-p53 and treated with increasing doses of 
cisplatin (CDDP) for 16 hours and released for 24 hours. Data are expressed as percentage of viable cells 
respect to the sh-ctrl untreated parental cells and represent the mean (±SD) of 3 biological replicates. 
Statistical significance was determined by two- way ANOVA test; a multiple comparison analysis was done 
to determine significant differences among groups. p-value is reported in the graph. B) Western Blot analysis 
evaluating p53 expression in parental and PT-res clones, transduced with sh- ctrl or sh-p53 used in (A). 
GAPDH was used as loading control. Adapted from Lorenzon et al., 2020. 
Results showed that down modulation of p53 expression induced a marked cell death 
level per se, suggesting that MDAH cells are addicted to the expression of mutant TP53, 
rendering the evaluation of PT-sensitivity difficult to be evaluated in this experimental 
setting. 
Based on these results, we used a different approach and evaluated if the double mutant 
p53S185G/R273H  could play a role in some of the biological characteristics of the PT-res 
clones. We used the p53NULL EOC cell line, SKOV-3, in which we overexpressed the 
p53R273H or the p53S185G/R273H proteins, by transfecting them with pEGFP plasmids carrying 
the two different mutants. Although the transfecting efficacy ensures that the two proteins 
were equally expressed, the double mutant p53S185G/R273H had a higher phosphorylation of 
Ser 37 and, partially, of Ser 15 of p53, accompanied by a decreased expression of 
NCAPH (Figure 40A) mimicking what previously observed in PT-res clones (Figure 36B). 
Using SKOV-3 over-expressing cells, we also examined whether the regulation of genes 
belonging to the p53MUT signature (Girardini et al., 2011) was altered. Through qRT-PCR 
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analyses we evaluated the expression of the two genes differentially regulated in MDAH 
PT-res clones (Figure 40B). A slightly decreased mRNA expression of NCAPH and a 
consistent increased mRNA expression for DEPDC1 was observed in  SKOV-3 double 
mutant p53S185G/R273H when compared to p53R273H over-expressing cells (Figure 40B). On 
the contrary, the expression of CCNE2 was not modified by p53S185G/R273H in this model 




Figure 40. SKOV-3 p53S185/R273H over-expressing cells mimick MDAH PT-res clones gene regulation. 
(A) Western blot analyses evaluating the expression of DNA-PK, NCAPH, phosphorylated p53 (Ser 15 and 
Ser37) in SKOV-3 cells stably transfected with pEGFP-p53R273H or pEGFP-p53R273H/S185G double mutant. 
Cells were treated or not with CDDP for 16 hours. Tubulin was used as loading control. (B) qRT-PCR 
analyses of the indicated genes in SKOV-3 p53R273H or p53S185G/R273H over-expressing cells. mRNA levels 
were analyzed in triplicate and normalized using GAPDH housekeeping gene. Data are expressed as fold of 
mRNA expression in  p53R273H or p53S185G/R273H over-expressing cells respect to empty condition and 
represent the mean (± SD) of at least of three independent experiments. Statistical significance was 
determined by a two-tailed unpaired Student’s t-test (*p < 0.05 and **p < 0.01). Adapted from Lorenzon et 
al., 2020. 
 
Importantly, the stable expression of p53S185G/R273H increased the resistance to platinum of 
SKOV-3 cells significantly better than the p53R273H single mutant (Figure 41), supporting a 





Figure 41. The expression of p53S185G/R273H induces an increase of SKOV-3 cells platinum resistance. 
Nonlinear regression analysis of cell viability assay of cells described above and treated with increasing 
doses of CDDP for 72 hours. Data are expressed as percentage of viable cells respect to the untreated cells 
and represent the mean (±SD) of 3 biological replicates. Fisher’s exact test was used to calculate the global 
p-value reported in the graph. Adapted from Lorenzon et al., 2020. 
 
To understand if the increased resistance to platinum of SKOV-3 p53S185G/R273H transfected 
cells was accompanied by an increased number of multinucleated cells, we evaluated the 
number of MNGCs in SKOV-3 cells transfected with p53R273H or with p53S185G/R273H by 
immunofluorescence analyses, specifically looking at the number of multinucleated in cells 
expressing the p53 proteins.  
Results showed that p53S185G/R273H markedly increased the number of multinucleated 
SKOV-3 cells (Figure 42A) respect to cells expressing p53R273H. Nevertheless, 
p53S185G/R273H expression reduced SKOV-3 cell growth when compared to cells expressing 
p53R273H single mutant (Figure 42B), overall, recapitulating most of the phenotype 
observed in PT-res cells.  
 

































Figure 42. SKOV-3 p53S185/R273H over-expressing cells are characterized by an increased number of 




double mutant stained for F-actin (red) and p53 (green). Nuclei are 
pseudo colored in blue (TO-PRO-3). Bottom panels show the indicated zoomed area for each condition (2× 
zoom) in which white arrows indicate multinucleated cells. Scale bar = 44 μm. On the right, the number of 
multinucleated cells counted among p53 positive cells/field is reported (mean ± SD). The entire coverslips 
were counted. Statistical significance was determined by a two-tailed unpaired Student’s t-test (*p < 0.05 and 
**p < 0.01). (B) Growth curves of SKOV-3 cells stably transfected with p53
R273H or p53
S185G/R273H double 
mutant. Data are expressed as fold increase with respect to day 0. Global statistical significance was 











The development of platinum resistance seems a dynamic process. Patients who initially 
respond to platinum-based chemotherapy end up becoming resistant. This suggests that it 
is necessary to investigate the mechanisms at the base of resistance development (Tapia 
and Diaz-Padilla, 2013). In this PhD thesis, we reported the selection of seven isogenic 
cisplatin resistant cell lines derived from high grade EOC, and the molecular and biological 
characterization of three of them: MDAH-2774, TOV-112D and OVSAHO. To our 
knowledge this is the first report comparing three different EOC models of acquired 
resistance to cisplatin. Through this work strategy we were able to establish platinum 
resistance as a multifactorial and complex molecular process caused by different 
molecular alterations, although common phenotypic changes can be observed.  
One important feature of the platinum resistant cells selected was the common ability to 
resolve platinum-induced DNA damage (Figure 20), strengthened by the concomitant 
altered expression of selected transporters of the drug (Figure 22). These two 
characteristics of PT-res cells then resulted in a decreased accumulation of DNA damages 
(i.e H2AX expression). We observed that cross-resistance to other drugs often used in 
the therapy of platinum resistant ovarian cancer patients (like taxol and doxorubicin), was 
cell-type specific (Figure 13). Thus, identifying biomarkers of cross-resistance would end in 
significant clinical benefit for patients, avoiding ineffective treatments.  
Interestingly, we have observed, at least in vitro, that the acquired resistant phenotype is 
maintained regardless the presence or absence of platinum in cell culture medium, 
suggesting that the clinical hypothesis postulating that it is worth to re-use platinum based 
therapies after a platinum-free interval, could be used as a therapeutic strategy only in 
platinum-sensitive ovarian cancer patients.  
Another common alteration due to the acquisition of the resistant phenotype was an 
evident morphological change in PT-resistant cells respect to parental ones (Figure 15). 
This involved the reorganization of cytoskeleton (Figure 17), cell-cell junctions (Figure 18) 
and ability to adhere to mesothelium layer (Figure 19), suggesting that EMT and MET 
processes could have a role in a different response to platinum treatment (Figure 16). This 
result was also sustained by a different expression of SNAIL, TWIST-1 and ZEB1 in our 
PT-resistant cells (Figure 16), indicating that the resistant phenotype is accompanied by 
an induction of EMT-like process. All these findings encourage us to further investigate the 
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driven mechanisms of increased ability to disseminate in the peritoneal cavity and to 
adhere at distant sites as key properties of PT-resistant cells. 
In the second part of this work we more deeply characterized several PT-resistant clones 
derived from single-cell cloning selection of MDAH-2774 PT-resistant pools. We reported 
that these cells showed an impaired growth rate respect to parental ones (Figure 26A), a 
deregulated cell division (Figure 28A and 31) with the appearance of a subpopulation of 
larger, multinucleated giant cells (MNGCs), not present in parental cells (Figure 26B and 
30). It is described that the proportion of MNGCs increases markedly under stressful 
conditions. This increase can be provoked by replicative stress, hypoxia and after 
exposure to anticancer agents (as chemotherapy) (Parekh et al., 2018; Mirzayans et al., 
2017; Mirzayans et al., 2018; Mittal et al., 2017). Although giant cells are often scored as 
“dead” because of their state of dormancy, they are associated with metastasis and 
resistance to chemotherapy, so targeting giant cells before they can promote tumor 
repopulation might be an effective anti-cancer strategy (Mirzayans et al., 2018). MNGCs 
secrete soluble signaling factors, including ROS, collectively known as SASP or 
senescence associated secretory phenotype in which TP53 plays crucial roles. In 
particular it has been proposed that SASP suppresses or promotes tumorigenesis 
depending on the TP53 status (Watanabe et al., 2017). This is coherent with the higher 
production of ROS levels we observed in MDAH PT-res cells (Figure 33). It is relevant to 
note that caspase 3 activation (Figure 32), in our model, could be also linked to an 
apoptosis-independent function, pro-survival, given than it has been already described as 
soluble factor characterizing the SASP phenotype of MNGCs (Mirzayans et al., 2017; 
Mirzayans et al., 2016; Liu et al., 2015). Which is the role of TP53MUT in the generation of 
MNGCs is still unclear but since it has been proposed that MNGCs could represent an 
adaptive response of apoptosis-reluctant cells, TP53MUT could play a pivotal role in 
allowing aberrant mitotic cells to complete the M phase and eventually survive as MNGCs. 
Here we report that MDAH PT-resistant cells acquired, under the pressure of platinum 
selection, a secondary mutation (the S185G missense substitution) in TP53, in addition to 
the already present R273H pathogenic missense substitution (Figure 38). This 
p53S185G/R273H double mutant was found in all tested clones and pools. Yet, while the 
R273H substitution is homozygous in MDAH cells the S185G seems to be heterozygous. 
p53S185G is still categorized as a mutation of unknown significance and it has been 
described in the Cosmic database only in one case of ovarian endometrioid carcinoma 
and one case of esophageal carcinoma. Surprisingly, in both cases p53S185G substitution 
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was found in tumors with known pathogenic TP53 mutations (Ralhan et al., 2000; 
Neungton et al., 2002). It is therefore possible that the S185G mutation confers a specific 
advantage only to a p53MUT protein.  
To understand if p53S185G mutation appeared as the selection of an already existing 
missense mutation or as a platinum-induced mutation we deeply sequenced the parental 
cells (median coverage depth for TP53 was 5600X) in search of possible MDAH subclones 
carrying this substitution. We found that MDAH parental cells presented only the p53R273H 
mutation already described, suggesting that pressure of PT selection induced the 
appearance of this co-occurring mutation. 
p53S185G appearance was linked to higher pS37 phosphorylation levels, not only in PT-res 
clones but also in transfected SKOV-3 (p53NULL) cells, supposing its involvement in 
increased activity to an already mutated TP53 (Figure 36B and 39). How p53S185G affects 
pS37 is still unknown, although we could likely exclude that it could be due to an increased 
association between TP53 and DNA-PKCS (Figure 37A). Interestingly, others and we 
demonstrated that TP53MUT specifically regulates the transcription of genes involved in the 
mitotic process (Girardini et al., 2011; Sonego et al., 2013), supporting the possibility that it 
confers additional surviving possibilities to cells with aberrant mitosis, otherwise committed 
to die for mitotic catastrophe. The deregulation of some of these genes (i.e. CCNE2, 
DEPDC1, NCAPH and C21orf45) observed in PT-res MDAH clones and partially in SKOV-
3 cells is in line with this possibility (Figure 34 and 40). However, further studies are 
necessary to clarify the molecular mechanisms through which TP53MUT contributes to 
MNGCs formation. In addition, the ectopic expression of p53S185G/R273H had functional 
consequences since it significantly increased the resistance to PT in SKOV-3 cells and 
was associated with PT-resistance in MDAH cells (Figure 41). Based on the phenotypes 
observed in MDAH PT-res cells, we hypothesized that the more active p53S185G/R273H 
protein could be partially responsible for the bypass of the G2/M checkpoints normally 
activated upon DNA damage by regulating mitotic regulators. This altered regulation 
eventually resulted in a deregulated cell division with the appearance of large MNGCs. 
Although we partially proved this point using the SKOV-3 model, we cannot verify the 
effective contribution of TP53 mutation on the phenotypes observed in MDAH cells, since 
these cells seem to be addicted to mutant TP53 expression. Therefore, more experiments 
and more appropriate study models are needed to definitively prove this point.  
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However, TOV-112D and OVSAHO PT-resistant cell lines, that were generated with the 
same “pulse” method of MDAH cells (Figure 11), did not show defects in cell proliferation, 
caspase 3 activation and MNGCs formation. We sequenced TP53 in both OVSAHO and 
TOV112D cells and, while we confirmed the presence of the mutation reported in the 
literature (R342* and R175H, respectively), we did not observe in these cells the 
appearance of the additional p53S185G, indirectly supporting its involvement in the typical 
phenotype of MDAH PT-res cells. The Gene Set Enrichment Analysis (GSEA) of MDAH, 
OVSAHO and TOV112D PT-res cells we recently performed, evidenced that only MDAH 
PT-res cells had alteration in pathways controlling cell cycle progression and cell division 
(Sonego et al., 2017). 
Overall our data demonstrated that platinum chemotherapy could induce additional 
mutations in TP53 and that the expression of double mutant p53R273H/S185G could affect the 
generation of PT-resistance by regulating the progression trough mitosis. Future more 
detailed works will be necessary to specifically unveil the underlying molecular 
mechanisms. 
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Materials and Methods 
 
 
5.1 Cell cultures 
MDAH-2774 (CRL-10303), TOV-112D (CRL-11731), TOV-21G (CRL-11730), SKOV-3 
(HTB-77), ES-2 (CRL-1978) cells were from ATCC; OVCAR-8 (60-0507712) cells were 
from The National Cancer Institute Developmental Therapeutics Program Tumor 
Repository; while OVSAHO (JCRB0098) cells were from JCRB Cell Bank. All cell lines 
were maintained in RPMI-1640 medium (Sigma-Aldrich Co.) containing 10% heat-
inactivated FBS, 100 U/ml penicillin and streptomycin (complete medium) at 37°C in a 5% 
CO2 atmosphere. Cisplatin-resistant (PT-res) isogenic cells were generated by treating 
EOC parental cells for growth for 2 hours with a cisplatin dose 10-fold higher than the 
calculated IC50 and then allowing to re-grow in drug-free complete medium (pulse 
treatment). The subsequent drug treatment was administrated when the cells reached 
again a 70-80% of confluence. In total PT-res cells received 20 pulse treatments. At the 
end of treatments, a single cell cloning was performed in order to evaluate the 
homogeneity of these PT-res cell populations. The cisplatin IC50 of clones was tested. All 
the experiments were performed with cells kept in cisplatin-free medium for 2 months 
unless otherwise stated. All cell lines were routinely authenticated in our lab using the Cell 
ID TM System (Promega) protocol and using Genemapper ID Ver 3.2.1 to identify DNA 
STR profiles. 
 
5.2 Compounds and drugs treatment 
Cisplatin was purchased from TEVA (Italia), Paclitaxel (TAXOL) from ACTAVIS (Dublin, 
Ireland) and Doxorubicin from Ebewe (Italia). Cycloheximide (CHX) was purchased from 
Sigma. ROS analyses were done using 2',7'-dichlorodihydrofluorescein diacetate (H2-
DCF-DA) (Sigma). 2′,7′-Dichlorofluorescin diacetate is a cell-permeable non-fluorescent 
probe. 2′,7′-Dichlorofluorescin diacetate is de-esterified intracellularly and turns to highly 
fluorescent 2′,7′-dichlorofluorescein upon oxidation. Double thymidine block was 
performed incubating cells with thymidine (2.5 mM), acquired from Sigma. 
 
5.3 Cell viability assay 
Dose-response curves were performed essentially as described previously (Dall’Acqua et 
al., 2017). EOC cells were seeded in 96-well culture plates and treated with increasing 
doses of cisplatin, Taxol or Doxorubicin for 72 hours. For dose-response curves of p53-
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silenced MDAH, cells were seeded in 96-well culture plates and after 24 hours transduced 
with sh-ctrl or sh-p53 lentiviral particles (Mission Sigma TRCN0000003756). 48 hours after 
transduction cells were treated with increasing doses of CDDP for 16 hours and released 
with complete medium for 24 hours. Cell viability was determined using the CellTiter 96 
Aqueous cell proliferation assay kit (Promega). Absorbance was detected at 492 nm using 
a microplate reader (Infinite M1000 Pro, Tecan).     
 
5.4 Vectors and transfections 
The p53R273H mutant was subcloned in the pEGFP-C1 vector (Clontech) and in the 
pLPC vector (Provided by Dr R. Maestro) from the pCMV/Neo-p53R273H 
(Addgene#16439) into the BamHI restriction site. The pEGFP-p53 and pLPC-p53 double 
mutant were generated using a QuikChange Site-Directed Mutagenesis Kit (Agilent) using 
oligonucleotides carrying the indicated mutation. Plasmids were transfected in SKOV-3 
cells using FuGENE HD Transfection Reagent (Promega) according to the manufacturer’s 
indications. Stable expressing clones were selected by culturing cells with G418 (0.5 
mg/ml) (pEGFP) or puromycin (1 ug/ml) (pLPC). For lentiviral production, 293FT cells 
(Invitrogen) were co-transfected, using a standard calcium phosphate precipitation, with 
the lentiviral based shRNA constructs (pLKO) and lentiviral vectors pGag-Pol (Sigma) and 
pVSV-G (Invitrogen). Seventy-two hours after transfection, medium containing viral 
particles was used to transduce EOC cell lines. pLKO vectors encoding for control and p53 
(TRCN0000003756) shRNAs were purchased from Sigma. 
 
5.5 Cell cycle analysis by flow cytometry 
EOC cells (pools) were plated in 60-mm dishes (8  ×  105 cells/dish) and after 24  hours 
treated with cisplatin. Cells were harvested at the indicated time points. EOC cells (MDAH 
clones) were plated in 60 mm dishes and collected after 48 hours for the exponentially 
growing condition analysis. For the synchronized cells condition was done a double 
thymidine block to arrest cells in G1/S phase. Cells were then released and collected at 
the indicated time points for the cell cycle analysis. Once harvested, cells were washed 
with 1x PBS, fixed in ice-cold 70% ethanol adding drop wise to the pellet while vortexing to 
minimize clumping and stored at -20 °C overnight. Fixed cells were then washed in 1x 
PBS and re-suspended in propidium iodide (PI) staining solution (50 g/ml PI + 200 g/ml 
RNaseA, in 1x PBS). Stained cells were subjected to flow cytometry analysis with a BD 
FACScan or a BD FACSCalibur flow cytometer. Distribution of cells in G1, S and G2/M 
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phases of the cell cycle was analyzed with the WinMDI2.9 software as described (Fabris et 
al., 2015) for EOC pools, with ModFit LT software for MDAH clones. Plots of MDAH 
clones were realized with FlowJo software. 
 
5.6 Preparation of cell lysates, Immunoblotting, and Immunoprecipitation 
Cell lysates were prepared using cold RIPA buffer [150 mM NaCl, 50 mM TRIS-HCl (pH 
8), 0.1% SDS, 1% Igepal, and 0.5% NP-40] containing proteases inhibitor cocktail 
(Roche), phosphatase inhibitors (1 mM Na3VO4 and 10 mM NaF, Sigma-Aldrich) plus 1 
mM DTT. Protein concentrations were determined using the Bio-Rad protein assay (Bio-
Rad). For immunoblotting, equal concentrations of protein samples were separated by 4–
20% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) (Criterion precast gel, Bio-
Rad) and blotted onto a nitrocellulose membrane (Amersham, GE Healthcare). 
Immunoprecipitations were performed using 600μg of cell lysate in HNTG buffer (20 mM 
HEPES, 150 mM NaCl, 10% glycerol, 0.1% Triton X-100) plus 1 μg of anti DNA-PKcs 
antibody (H-163 sc-9051, Santa Cruz Inc.) and incubating overnight at 4°C. The 
immunocomplexes were precipitated by adding protein A agarose-conjugated for 
additional 1 hours and 30 min at 4°C and finally separated on SDS-PAGE, for western blot 
analysis. Immunoblotting were performed using the following primary antibodies: DNA-
PKcs (H-163 sc-9051, 1:1000), cyclin A (H-432 sc-751, 1:200), cyclin B1 (GNS1 sc-245, 
1:200), phospho Rb (Ser780) (sc-12901, 1:500), stathmin (E-3 sc-55531, 1:1000), p53 
(DO-1 sc-126, 1:1000) and vinculin (7F9 sc-73614, 1:1000), Twist-1 (Twist2C1a sc-81417, 
1:200) were from Santa Cruz Inc.; phospho-p53 (Ser15) (#9284, 1:500), phospho-p53 
(Ser37) (#9289, 1:500), phospho-H3 (Ser10) (D7N8E #53348, 1:500), Histone H3 (D1H2 
#4499, 1:750), phospho-cdc2 (Tyr15) (10A11 #4539, 1:500), Zeb1 (D80D3 #3396, 1:500), 
Slug (C19G7 #9585, 1:500), Snail (C15D3 #3879, 1:1000) were from Cell Signaling 
Technology; cyclin E2 (EP454Y ab40890, 1:1000), NCAPH (ab154105, 1:300) were from 
Abcam; DEPDC1 (1:500) was a kind gift from Prof G. Del Sal (Trieste University); GAPDH 
(6C5 CB1001, 1:1000), phospho-histone H2AX (Ser139) (H2AX) (JBW301 #05-636, 
1:500), were from EMD Millipore; CDK1 (C12720, 1:500) was from BD Transduction 
Laboratories; α-tubulin (DM1A T9026, 1:5000) was from Sigma-Aldrich. 
 
5.7 Protein stability 
p53 protein stability was evaluated in MDAH-2774 parental and PT-res clones treated with 
CHX (10 mg/ml) for the indicated time points. The p53 expression was calculated as 
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remaining fraction respect to T0 (mean ± SD of 3 different experiments), normalized 
respect to GAPDH expression. 
 
5.8 RNA isolation and Real-time polymerase chain reaction 
Total RNA was isolated using TriZol reagent (Life Technologies) following the 
manufacturer’s instructions. 2 g of total RNA was retro-transcribed using random 
hexamers and the AMV Reverse Transcriptase (Promega). 1/20 of the obtained cDNAs 
were then amplified using primers for the human FAM64A, CENPA, BUB1, NCAPH, 
C21orf45, DEPDC1, CCNE2, WDR67, CPSF6, EPB41L (Girardini et al., 2011; Sonego et 
al., 2013). Standard curves (10-fold dilution from 10-1 to 10-4 attomoles) were prepared and 
analyzed by quantitative reverse transcription polymerase chain reaction (qRT-PCR) using 
the CFX96 Real-time PCR Detection System (Bio-Rad). 
 
5.9 In vitro cell proliferation 
For growth curve analyses, MDAH-2774 parental and PT-res pools (pool#1 and pool#2) 
and SKOV-3 cells stably transfected with pLPC- p53R273H or pEGFP-p53R273H/S185G double 
mutant were cultured in 6-well plates. Viable cells were counted daily in triplicate for 5 
days, by trypan-blue dye exclusion method. For cell proliferation, PT-res clones (#12, #19, 
#42 and #51) were seeded in sextuplicate in 96-well plates and cell proliferation was 
determined daily (for 5 days) by MTS assay using the CellTiter 96 AQueous cell 
proliferation assay kit (Promega). All experiments were repeated at least three times. 
 
5. 10 EOC adhesion on mesothelial cells and Immunofluorescence analyses 
Mesothelial cells (derived from pleural lavage) were seeded on glass coverslips and 
allowed to grow until they reached complete confluence. 1.5  ×  105 EOC cells detached 
with 5  mM EDTA, labeled with vital green fluorescent lipophilic tracer DiO (Invitrogen) and 
washed with PBS were then plated on mesothelial layer in serum free medium for 
24  hours. 
For immunofluorescence analyses cells plated on coverslips were fixed in PBS-4% 
paraformaldehyde (PFA) at room temperature (RT), blocked in PBS-1% bovine serum 
albumin (BSA), permeabilized in PBS 0.2% Triton X-100. Stains were performed with 
primary antibodies: anti-α-tubulin-fluorescein isothiocyanate (FITC) (clone DH1A, F2168, 
1:150), -tubulin (clone GTU-88, T6557, 1:1000) (Sigma Aldrich); ZO-1 (D7D12 #8193, 
1:50), cleaved caspase 3 (Asp175) (#9661, 1:300), phospho- histone H3 (Ser10) (D7N8E 
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#53348, 1:300) (Cell Signaling), p53 (DO-1 sc-126, 1:200) from Santa Cruz Inc.; and -
catenin (610253, 1:50) (BD Biosciences). Then samples were washed in PBS and 
incubated with secondary antibodies (Alexa-Fluor 488-, 568- or 633- conjugated anti-
mouse or anti-rabbit antibodies; Invitrogen) for 1  hour at RT. PI (5  μg/ml + RNaseA) or 
TO-PRO-3 iodide (Invitrogen) were used to visualize nuclei and Alexa-Fluor 647- or 546-
Phalloidin (Invitrogen) for F-actin staining. Coverslips were mounted with glycerol/0.25% 
DABCO and analyzed using the Leica Time Lapse AF6000LX workstation, the TCS-SP2 
or the TCS-SP8 Confocal Systems (Leica Microsystems Heidelberg GmbH) interfaced with 
the Leica Confocal Software (LCS) or the Leica Application Suite (LAS) software. 
 
5.11 Next Generation Sequencing (NGS) 
For TP53 sequencing of PT-res pool cells, genomic DNA was extracted from cultured cells 
using Maxwell 16 DNA purification kit (Promega). 50 ng of genomic DNA was amplified 
with TruSeq Custom Amplicon kit (TSCA, Illumina) specially designed for the targeted 
sequencing of TP53 (13 amplicons) among others. Libraries were run in an Illumina MiSeq 
instrument achieving a median coverage >1000 reads. Data were aligned to human 
reference genome hg18 and analyzed, after quality control, using Variant Studio and IGV 
program, reporting only variants with a mutant allelic frequency (MAF) greater than 5%. 
We considered not only variants inside the coding sequence, but also the ones inside the 
5’-, 3’-untranslated regions (UTRs) and inside splicing regulatory elements (Diederichs S 
et al 2016, http://p53.iarc.fr/TP53GeneVariations.aspx). Validation of NGS data was 
performed on PT-res clones by Sanger method. 
 
5.12 Cisplatin-DNA (Pt-DNA) adduct detection by Dot-blot 
To detect cisplatin-DNA adducts, genomic DNA was isolated using the Maxwell® DNA-
purification kit (Promega) from cells treated as indicated. DNA (500  ng) was denatured at 
100  °C for 10  min and spotted onto nitrocellulose membranes (Hybond C; Amersham) 
using a dot-blot apparatus (Easy-Titer® ELIFA, Pierce). The membranes were then baked 
for 2  hours at 80  °C and subjected to standard Immunoblot assay using an anti-cisplatin-
DNA Adducts (1:500) antibody (EMD Millipore, clone ICR4). 
 
5.13 Reactive Oxygen Species (ROS) analyses 
To determine the quantification of intracellular ROS, cells were plated in 60 mm dishes 
and treated or not with CDDP for 24 hours. After treatment, cells were incubated with 2',7'-
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dichlorodihydrofluorescein diacetate (H2-DCF-DA) (Sigma) 2,5 M in RPMI without phenol 
red for 30 minutes at 37°C and 5% CO2. Cells were washed in PBS 1X and collected by 
trypsinization in 1 ml of PBS 1X and analyzed using the BD FACSCanto II flow 
cytometer. The H2-DCF-DA molecule was excited with an excitation wavelength of 504 nm 
and the emission wavelength of 529 nm was detected and recorded by the instrument. For 
each sample were analyzed 20000 events, applying a gating strategy to exclude the 
debris. All the data were analyzed using the BD FACSDiva Software. 
 
5.14 Double thymidine block 
To synchronize cells a double thymidine block was performed. Cells were plated in 60 mm 
dishes and after 24 hours incubated with thymidine (2.5 mM) for 16 hours. Cells were then 
washed with 1x PBS and incubated with fresh complete medium for 9 hours before the 
second round of thymidine (2.5 mM) for 16 hours. Synchronized cells were then washed 
with 1x phosphate-buffered saline (PBS), released with complete medium and collected at 
the indicated time points for analysis of cell cycle by propidium iodide (PI)-DNA staining, or 
analysis of protein by Western blot. 
 
5.15 Statistical analyses 
All statistical analysis was done using Graphpad Prism 8 software and appropriate 
methods were employed. Standard deviations were used for designating error bars. 
Comparisons of two different groups were done with the help of Student's t-test and 
multiple groups were compared using ANOVA test. p-value ≤ 0.05 was considered 















Real-time PCR primers 
 
Name Sequence (5’-3’) 
BUB1 f ATTCAAGCCACAGAGTGGAGCAG 
BUB1 r AGAACTTGTGTTGGCAACCTTATGTG 
C21ORF45 f GCGACTCGCTGAGCTGGGTG 
C21ORF45 r CCCCGCGCAGCACAAAGTCT 
CCNE2 f TGAGCCGAGCGGTAGCTGGT 
CCNE2 r GGGCTGGGGCTGCTGCTTAG 
CENPA f CTTCCTCCCATCAACACAGTCG 
CENPA r TGCTTCTGCTGCCTCTTGTAGG 
CPSF6 f AGGGGCTGTTCCTGGTGGGG 
CPSF6 r GGCCCAGCTAGAGGAGGAGGC 
DEPDC1 f TGGGTATTATCTGCCATGAAGTGCCT 
DEPDC1 r AGGTTGCAGCAAGCCCAAAATGT 
EPB41L4B f CGACGGGACCGAAGTGAGCG 
EPB41L4B r CAGTGCGCAACCTGGGCAGA 
FAM64A f CTCCAGGCTGCAGCTCGCTC 
FAM64A r CAGCCGGGTGCTCTTCTGGC 
NCAPH f GAGGAGCCTGCCCCCTGTCA 
NCAPH r TGGGCCTCCTGCTGCTGACT 
WDR67 f AGGCAACAAGGAGAGCGGCA 
WDR67 r AGCAGTCGCCTGTGCCATCA 
 
 
PCR and sequencing primers 
 
Name Sequence (5’-3’) 
p53 exon5 f GCCGTCTTCCAGTTGCTTTA 
p53 exon5 r ACACGCAAATTTCCTTCCAC 
p53 exon8 f GGGAGTAGATGGAGCCTGGT 
p53 exon8 r GTTGGGCAGTGCTAGGAAAG 
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